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BACKGROUND:  Worldwide, prostate cancer is the second most frequent cancer in 
males, and the sixth cause of cancer related deaths. Many genetic and epigenetic 
alterations have already been described, although it is still difficult to differentiate a 
clinically insignificant PCa from an aggressive one, meaning that the exact mechanisms 
surrounding proliferation, differentiation and tumor progression still need to be explored. 
Recently, germline mutations in HOXB13, a homeobox transcription factor gene that is 
important in prostate development, were discovered, being HOXB13 p.Gly84Glu (G84E) 
the first major genetic mutation associated with familial PCa.  
 
AIMS: The main goal of this Master´s Thesis was to search for mutations in the 
HOXB13 gene at the somatic level, and eventually in the germline, and to gain insights 
about its role in prostate carcinogenesis by using in vitro models. In addition, we sought to 
characterize HOXB13 mRNA expression pattern in normal prostate tissues and in 
prostate carcinomas belonging to different molecular subgroups.  
 
METHODOLOGY: To search for mutations in HOXB13, we performed Sanger 
sequencing in 178 primary tumor samples obtained from prostatectomies, from a 
consecutive series of 200 clinically localized PCa. To investigate the potential oncogenic 
role of HOXB13 and of its mutated forms (the previously described G84E and the new 
mutation, discovered after Sanger sequencing), we induced de novo overexpression of 
these three forms in two prostate cell lines, 22Rv1 and PNT2, by transfecting these cells 
with three expression vectors. The wild-type HOXB13 expressing vector was acquired, 
and the mutated vectors were created by inducing site-directed mutagenesis in the wild-
type vector. Functional studies were then performed to evaluate cell proliferation and cell 
apoptosis in the PNT2-derived cell populations. To evaluate HOXB13 mRNA expression 
levels in NPTs and in prostate carcinomas, we used data obtained from exon-level 
expression microarrays, which had already been performed by our group.  
 
RESULTS AND DISCUSSION: We found a novel nonsynonymous mutation, 
p.Ala128Asp (A128D), in the HOXB13 gene, initially in tumor tissue and then also in a 
blood sample of the patient. This novel germline mutation seems to be damaging to 
protein function, emphasizing that HOXB13 is involved in prostate carcinogenesis. By 
performing phenotypic assays we observed that HOXB13 stimulates cell growth and that 
one of its mutated forms, A128D, causes a decrease in apoptotic rates in PNT2-cells, in 
the absence of androgens. Both observations suggest a possible oncogenic role for 
HOXB13 in prostate carcinogenesis. We also report that HOXB13 is particularly 
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overexpressed in prostate carcinomas with ETV1 rearrangements, and further studies are 
needed to study this correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XXI 
 
INTRODUÇÃO: O cancro da próstata é o segundo tipo de cancro mais frequente 
nos homens em todo o mundo, e a sexta causa de morte por cancro. Já foram descritas 
várias alterações genéticas e epigenéticas, no entanto continua a ser difícil distinguir um 
carcinoma da próstata clinicamente insignificante de um agressivo, o que significa que os 
mecanismos exactos de proliferação, diferenciação e progressão tumoral ainda precisam 
de ser explorados. Recentemente foram descritas mutações germinativas no gene 
HOXB13, um factor de transcrição homeobox importante no desenvolvimento da próstata, 
sendo a variante p.Gly84Glu (G84E) a primeira grande mutação genética a ser associada 
a cancro da próstata familiar.  
 
OBJECTIVOS: O principal objectivo desta Tese de Mestrado consistiu em procurar 
mutações no gene HOXB13 a nível somático, e eventualmente germinativo, e tentar 
perceber o seu papel na carcinogénese prostática através do uso de modelos in vitro. 
Adicionalmente, pretendíamos caracterizar o padrão de expressão do mRNA do HOXB13 
em tecidos normais prostáticos e em carcinomas prostáticos pertencentes a diferentes 
subgrupos moleculares.  
 
METODOLOGIA: Para a pesquisa de mutações no HOXB13, realizámos 
sequenciação de Sanger em 178 amostras de tumores primários obtidos através de 
prostatectomias, de uma série consecutiva de 200 carcinomas prostáticos clinicamente 
localizados. Para investigar um eventual potencial oncogénico do HOXB13, bem como 
das suas formas mutadas (a já descrita G84E e a nova mutação, descoberta após 
sequenciação de Sanger), induzimos a sobre-expressão de novo destas três formas em 
duas linhas celulares prostáticas, 22Rv1 e PNT2, através da transfeção destas células 
com três vectores de expressão. O vector de expressão para a forma nativa do HOXB13 
foi adquirido, e os vectores mutados foram criados através de mutagénese dirigida no 
vector original. Estudos funcionais foram então realizados para avaliar a proliferação 
celular e a apoptose nas populações celulares derivadas da PNT2. Para avaliar os níveis 
de expressão do mRNA do HOXB13 em tecidos normais prostáticos e em carcinomas 
prostáticos, usámos dados obtidos de microarrays de expressão ao nível exónico, que já 
tinham sido realizados pelo nosso grupo.   
 
RESULTADOS E DISCUSSÃO: Encontrámos uma nova mutação não sinónima, 
p.Ala128Asp (A128D), no gene HOXB13, inicialmente em tecido tumoral e depois 
também numa amostra de sangue periférico do paciente. Esta nova mutação germinativa 
parece ser prejudicial para a função da proteína, dando ênfase ao facto de que o 
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HOXB13 está envolvido na carcinogénese prostática. Através da realização de ensaios 
fenotípicos observámos que o HOXB13 estimula o crescimento celular e que uma das 
suas formas mutadas, A128D, causa uma diminuição da apoptose nas células PNT2, na 
ausência de androgénios. Estas duas observações sugerem um possível papel 
oncogénico para o HOXB13 na carcinogénese prostática. Também reportamos que este 
gene está particularmente sobre-expresso em carcinomas prostáticos com rearranjos 
envolvendo o ETV1, e são necessários mais estudos para perceber esta correlação.  
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1. Global Burden of Cancer 
Some years ago, heart diseases and pneumonia constituted the leading causes of 
death worldwide, however, with the improvement of diet and health conditions of the 
populations, these pathologies started to decrease. More recently, cancer, known as the 
XXIst century disease, rose to the first and the second positions, in developed and in 
developing countries, respectively, concerning causes of death (Jemal et al., 2011). Still, 
incidence rates in developed countries are twice those found in developing countries, but 
the mortality rates are alike. This is due to a late diagnosis and a lack of access to 
appropriate treatment in the latter. Nevertheless, incidence rates in developing world are 
also increasing, which is in part explained by the growth and aging of the population, 
along with an increase of unhealthy choices and behaviors, like sedentary, smoking and 
bad diet habits, that are typical of the western and industrialized countries (Ferlay et al., 
2010; Jemal et al., 2011).  
According to the GLOBOCAN statistics for 2008, 12.7 million cancer cases and 7.6 
million cancer related deaths are estimated to have occurred in the world, and 56% of 
these cases and 63% of these deaths occurred in developing countries. It is to note that a 
substantial amount of cancer cases and deaths could be avoided through the adoption of 
healthier habits, vaccination, and ultimately, with early detection and appropriate 
treatment (Ferlay et al., 2010; Jemal et al., 2011). 
2. The Prostate  
2.1 Anatomy and Histology of the Prostatic Gland  
The prostate gland is a male accessory organ with a size of a walnut that reaches 
the weight of approximately 20g by the age of 25 to 30 years. It resembles an inverted 
pyramid with an apex and a basis, and resides between the pelvic floor and the urinary 
bladder. In the periphery, the prostate is surrounded by a thin layer of connective tissue 
that forms the “true” capsule, and in the outside the pelvic fascia forms the “false” capsule 
(Dixon, 1999; Hammerich, 2009; McNeal, 1988). The prostatic gland is crucial for the 
secretion of fluids needed for semen nutrition (Joshua et al., 2008; Shen and Abate-Shen, 
2010; Verma and Rajesh, 2011). Even though the human prostate does not present a true 
lobular architecture, John E. McNeal developed a work through many years (McNeal, 
1969, 1981, 1988; Shen and Abate-Shen, 2010) in which he described a zonal 
architecture model, which is still widely accepted and used in the clinical practice (Dixon, 
1999; Selman, 2011; Shen and Abate-Shen, 2010). He described four distinct anatomic 
zones, which are represented in Figure 1. 
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Figure 1 - Schematic representation of the sagittal view of the prostate, showing anatomical 
subdivisions [adapted from (Verma and Rajesh, 2011)]. 
There are three glandular zones, which are the peripheral, the central and the 
transition zones (Dixon, 1999; Zhai et al., 2010). The peripheral zone makes up 70% of 
the volume of the glandular part of the prostate, comprising the prostatic glandular tissue 
at the apex and near the capsule, and its ducts, that open into the distal urethra to the 
verumontanum. Certain pathologies like chronic prostatitis, postinflammatory atrophy and 
carcinoma are more frequently observed in this zone. The central zone has the shape of a 
cone that surrounds the ejaculatory ducts and represents approximately 25% of the gland. 
Lastly, the transition zone consists in two small lobes of tissue surrounding the lateral and 
the anterior parts of the proximal urethra, occupying 5% of the prostate gland (Amin, 
2010; Dixon, 1999; Hammerich, 2009; Shen and Abate-Shen, 2010; Verma and Rajesh, 
2011; Zhai et al., 2010). Besides the glandular part of the prostate, McNeal also described 
a non-glandular zone, called anterior fibromuscular stroma (AFMS) that embraces about 
one-third of the entire gland. It is composed of smooth muscle and fibrous tissue and 
forms the convexity of the anterior external part of the gland. This structure is important for 
both voluntary and involuntary sphincter functions (Amin, 2010; Dixon, 1999; Hammerich, 
2009; Verma and Rajesh, 2011; Zhai et al., 2010).  
The prostatic gland is mainly constituted by three epithelial cell types, depending 
on the anatomical place. The prostatic glands and ducts are covered by secretory cells 
that are important for the normal secretory function of the prostate. Near the basal part of 
the secretory cells there is a basement membrane that is coated by basal cells. Between 
these two, lies an intermediate type of cells called transient amplifying. The last type of 
cells is of neuroendocrine kind and is responsible for the regulation of cell growth and 
secretory activity (Joshua et al., 2008; Shen and Abate-Shen, 2010).  
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2.2 Pathology of the prostatic gland  
Prostate diseases are chronic and progressive and need several years to develop. 
Benign prostatic hyperplasia (BPH) is a hyperplastic process, in which there is an 
increased number of epithelial and stromal cells and therefore prostatic enlargement, 
which results in symptoms in the lower urinary tract. BPH arises more frequently in the 
transition zone and it is a very common pathology that increases with aging. Although its 
etiology is not fully understood, it is known that androgens are required for its 
development and that inflammation might also be involved (Roehrborn, 2008; Sciarra et 
al., 2008).  
The most likely precursor lesion of prostate cancer (PCa) is high-grade prostatic 
intraepithelial neoplasia (HGPIN) and this idea emerged because of some resemblances 
between this lesion and PCa. These include co-localization in the peripheral zone, 
morphologic transitions, molecular and phenotypic similarities and also epidemiological 
data. In this lesion, cells already have neoplastic features and line the pre-existing acini 
and ducts. Nuclei are also enlarged and hyperchromatic, although variation is observed, 
and there is frequently a prominent nucleoli. There is also cell and nuclear crowding. It 
was postulated that HGPIN arises from the low-grade form of prostatic intraepithelial 
neoplasia (LGPIN), since its cells have a very similar morphology, with the exception of 
the prominent nucleoli (De Marzo et al., 2007; Joshua et al., 2008; Putzi and De Marzo, 
2000; Shen and Abate-Shen, 2010). A proposed model for the progression from a normal 
epithelium to PCa is represented in Figure 2. It takes several years and is accompanied 
by different molecular processes and alterations in important pathways characteristic from 
each stage (Sciarra et al., 2008; Shen and Abate-Shen, 2010).  
 
Figure 2 - Evolution from normal epithelium to carcinoma, passing by LGPIN and HGPIN [adapted from 
(Sciarra et al., 2008)]. 
In 1999, proliferative inflammatory atrophy (PIA) was proposed by Angelo De 
Marzo and his colleagues as being another possible precursor lesion for prostate cancer, 
and it is thought to occur earlier than prostatic intraepithelial neoplasia (PIN) lesions (De 
Marzo et al., 1999; De Marzo et al., 2003; Deutsch et al., 2004; Putzi and De Marzo, 
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2000). PIA lesions can be found near PIN lesions and near adenocarcinoma, and include 
simple atrophy and postatrophic hyperplasia, in association with variable grades of 
inflammation and stromal fibrosis (De Marzo et al., 2007; Wagenlehner et al., 2007). The 
cells observed in these lesions are highly proliferative and have low apoptotic rates 
(Joshua et al., 2008; Nakai and Nonomura, 2013; Sciarra et al., 2008). 
Finally, the last step in the pathway represented in Figure 2 is PCa, which was first 
described by the Egyptians (Shen and Abate-Shen, 2010). PCa is very heterogeneous 
and usually multifocal, and although there are several types of prostate tumors, 
adenocarcinoma is the most frequent one, accounting for 95% of all cases (Boyd et al., 
2012; Eble et al., 2004; Shen and Abate-Shen, 2010). PCa rarely present symptoms, 
mostly at the initial stages, and the symptoms may be similar to those referred for BPH 
(Eble et al., 2004; Hammerich, 2009). The phenotype of adenocarcinoma is typically 
luminal, with the glands lacking a basal membrane and a basal cell layer (Chrisofos et al., 
2007; Shen and Abate-Shen, 2010). PCa frequently metastasizes, mainly to the bones, 
but also to pleura, lung and liver (Shen and Abate-Shen, 2010). 
3. Prostate Cancer 
3.1 Epidemiology  
PCa is the most frequently diagnosed malignancy of male genital organs (Eble et 
al., 2004; Stasiewicz et al., 2012). Worldwide, it occupies the second position of the most 
common cancers in males, with 903,500 new cases, and is the sixth cause of cancer 
related deaths in men, with 258,400 deaths in 2008 (Figure 3) (Ferlay et al., 2010; Jemal 
et al., 2011).  
 
Figure 3 - Estimated new cancer cases and deaths in the world, by cancer sites [adapted from (Jemal et 
al., 2011)]. 
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Differences concerning incidence and mortality rates between developed and 
developing countries are shown in Figure 4. 
 
 
Figure 4 - Age-standardized prostate cancer incidence and mortality rates (W) per 100,000 in selected 
world areas [adapted from GLOBOCAN 2008 available at http://globocan.iarc.fr/factsheet.asp]. 
Incidence rates are much higher in economically developed countries of Europe, 
North America and Oceania (Jemal et al., 2011) and have been rising since the 
introduction of prostate-specific antigen (PSA) testing in the early 1990s (Jemal et al., 
2011; Schroder and Roobol, 2012; Wolf et al., 2010). The relevance of PSA screening for 
PCa diagnosis will be discussed further. Mortality rates, on the other hand, have been 
decreasing in developed regions, which might be related with an improvement of 
treatments. (Ferlay et al., 2010; Schroder and Roobol, 2012).   
In Portugal, PCa was the most frequently diagnosed cancer in men in 2008, with 
5,140 new cases representing 21.4% of all carcinomas, and the third leading cause of 
death, with 2,021 deaths making up 13.8% of all cancer-related deaths (Figure 5). These 
proportions are very similar to those seen in the rest of Europe (Ferlay et al., 2010). 
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Figure 5 - Estimated cancer incidence and mortality in Portugal in 2008 [adapted from GLOBOCAN 2008 
available at http://globocan.iarc.fr/factsheet.asp]. 
3.2 Etiology  
When compared to other types of cancers, for which some risk factors are known 
(smoking in lung cancer, for example), the causes of PCa remain mostly unknown 
(Gronberg, 2003). As prostate carcinomas are very heterogeneous, both genetic and 
environmental factors are expected to contribute for its etiology (Alvarez-Cubero et al., 
2012).  
Over the past years, many epidemiological studies have been trying to associate 
some risk factors with an increased risk of PCa, however the results remain controversial. 
The differences in incidence rates are thought to be explained, in part, by age, ethnicity, 
socioeconomic status, residence area, and environmental factors such as work place, 
lifestyle and diet (Alvarez-Cubero et al., 2012; Eble et al., 2004). Concerning diet, while a 
high intake of fat, animal proteins, processed meats and a high consumption of dairy 
foods have been associated with an increased risk of PCa development  (Deutsch et al., 
2004; Gronberg, 2003; Nelson et al., 2003), there are several dietary factors that appear 
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to have a protective effect against PCa (Table 1) (Damber, 2008; Deutsch et al., 2004; 
Nelson et al., 2003). 
Table 1 - Dietary factors that are thought to reduce PCa risk [adapted from (Deutsch et al., 2004)]. 
Dietary component Role 
Selenium Cell-cycle inhibition and apoptosis 
Vitamin E Antiproliferative action 
Cruciferous vegetables Cell-cycle inhibition 
Lycopene (tomatoes) Free radical scavenger 
Resveratrol Free radical scavenger and proapoptotic 
 
Although many risk factors have been suggested, only three are fully established, 
which are increasing age, ethnic origin and a positive family history of PCa (American 
Cancer Society: Cancer Facts & Figures 2012; Damber, 2008; Jemal, Bray, et al. 2011).  
In fact,  60% of the PCa cases are diagnosed in men with more than 65 years old, 
and about 97% in men with more than 50 years, with the mean age of diagnosis standing 
between 72 and 74 years (American Cancer Society: Cancer Facts & Figures 2012; 
Gronberg, 2003). This relationship is not entirely understood, but it is presumed that, with 
aging, gene expression alterations may occur in the prostate, mainly in genes associated 
with inflammation, senescence and oxidative stress (Shen and Abate-Shen, 2010). 
Regarding ethnic origin or race, it is known that the highest incident rates are 
observed in men with African ancestry, like Jamaicans and African Americans (American 
Cancer Society: Cancer Facts & Figures 2012). After black people, the Caucasians are 
the most affected, with the Asians having the lowest risk (Eble et al., 2004). 
An hereditary component is estimated to be present in 5-10% of all cases as 
observed by a clustering of PCa in some families (American Cancer Society: Cancer 
Facts & Figures 2012; Damber, 2008; Gronberg, 2003). Men with affected first-degree 
relatives have a two to three-fold increased risk for developing PCa when compared to the 
general population (Boyd et al., 2012; Schroeck et al., 2013) and the risk increases with a 
decrease in the age at diagnosis of the affected individuals and with the increase in the 
number of affected relatives (Gronberg, 2003). The aggregation of cases in families might 
be explained by the inheritance of mutations in genes that are associated with PCa 
(Damber, 2008). Some have already been identified, and will be discussed later. 
3.3 Screening 
In many countries PSA testing in combination with digital rectal examination (DRE) 
are used as screening tools for the early detection of PCa. PSA is a kallikrein-related 
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serine protease that is essentially produced by the epithelial cells from the ducts and acini 
of the prostatic gland. Its levels are typically very low, except when a disruption of the 
normal prostatic architecture occurs, causing its release to the circulation (Greene et al., 
2013; Shen and Abate-Shen, 2010).  
Men with suspicious DRE in conjunction with a PSA level above 4.0ng/ml are 
recommended to proceed to biopsy (Alvarez-Cubero et al., 2012; Heidenreich et al., 2008; 
Wolf et al., 2010). However, there is not a true cutoff value allowing the discrimination 
between cancer and non-cancer, meaning that the PSA test is not specific for cancer, but 
only for prostatic tissue. This is the major disadvantage of PSA testing, however there are 
no other biomarkers available (Alvarez-Cubero et al., 2012; Wolf et al., 2010). In fact, PSA 
levels can be elevated in other conditions besides PCa, such as BPH, prostatitis, and 
trauma, giving false-positive results (Alvarez-Cubero et al., 2012; Greene et al., 2013). 
PSA test can also produce false-negative results, so clinically important PCas could be 
missed (Alvarez-Cubero et al., 2012; Wolf et al., 2010). Despite being widely use, there is 
still a big controversy about the real benefits of PSA screening (Boyle and Levin, 2008) 
and it was estimated that 23 to 42% of PSA detected prostate cancers would never be 
diagnosed otherwise, indicating that PSA testing may lead to overdiagnosis and 
overtreatment. The main reason that favors PSA screening is the fact that it detects the 
illness at an early stage, allowing an effective and curative treatment, thus reducing 
mortality (Wolf et al., 2010). However, there is not enough proof that the reduced mortality 
observed in some countries, like in the USA, for example, is attributable to PSA screening 
(Damber, 2008; Wolf et al., 2010). 
Before proceeding to biopsy many factors should be taken into account. These 
factors include patient´s age and ethnicity, family history, biopsy history, comorbidities, as 
well as free and total PSA levels, PSA velocity and density (Greene et al., 2013). Current 
recommendations say that older men with a life expectancy lower than 10 years are 
unlikely to benefit from screening, but men belonging to high risk groups should pursue 
with screening. Concerning the general population, men should be informed about the 
pros and cons and make their personal decision (Boyle and Levin, 2008; Wolf et al., 
2010).  
Transrectal ultrasound imaging (TRUS) is also used as an aid-tool for patients with 
prostate problems. It allows the evaluation of the prostate volume and the delineation and 
measurement of potential lesions, but it has limited usefulness in the detection of prostate 
cancer (Eble et al., 2004).  
Nowadays it is still very difficult to distinguish an indolent cancer from an 
aggressive one, which will only be possible with a better understanding of the molecular 
mechanisms involved in PCa initiation and progression. This knowledge would allow the 
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identification of new biomarkers and new screening methods that could avoid 
overtreatment, and would also allow the development of new treatments with fewer risks 
(Shen and Abate-Shen, 2010; Wolf et al., 2010).  
3.4 Diagnosis 
When something suspicious is found with screening techniques, more exams are 
needed to confirm whether or not the patient has PCa and the examination of 
histopathological or cytological samples is required to make a definitive diagnosis 
(Damber, 2008). The gold standard method to obtain a sample is by transrectal 
ultrasound-guided core biopsies (Damber, 2008; Eble et al., 2004; Heidenreich et al., 
2008). It is recommended to take between 10 and 13 biopsy cores, which have a higher 
rate of detection than the traditional sextant method. Fine needle aspiration (FNA) 
cytology is another available technique, but is no longer widely used because of some 
disadvantages, like false-positives and the fact that it does not allow the evaluation of the 
Gleason grading (Heidenreich et al., 2008).  
3.4.1 Histopathological evaluation  
Histopathological grading is essential to access the aggressiveness of the tumor, 
to predict the outcome and also to choose the appropriate treatment (Buhmeida et al., 
2006; Damber, 2008; Harnden et al., 2007). In 1966 a grading system was created by 
Donald F. Gleason and nowadays it is the most widely used system. The Gleason grading 
is based on the glandular architectural pattern of the tumor and comprises five grades of 
differentiation (Figure 6 and Table 2), with grade one being the most differentiated and 
grade five the most undifferentiated (Buhmeida et al., 2006; Eble et al., 2004). 
 
 
Figure 6 - Modified Gleason system [adapted from (Epstein, 2010)]. 
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Table 2 - Gleason patterns and their main features [adapted from (Eble et al., 2004; Epstein, 2010)]. 
 
Gleason patterns 
 
Features 
 
Pattern 1 
 
Very well circumscribed nodule of packed glands with 
equal size and shape  which do not infiltrate. 
Pattern 2 
Round or oval glands with smooth ends, less uniform 
between each other than in pattern 1, wich can have 
minimal invasion. 
Pattern 3 
Discrete angular units with marked variation in shape 
and size, with infiltration in and amongst non-
neoplastic acini. 
Pattern 4 
Fused or cribiform glands, or defined glands with 
poorly formed glandular lumina. 
Pattern 5 
Almost complete loss of glandular lumina with 
formation of solid sheets, solid strands or single cells 
that invade the stroma. 
 
A grade must be present in at least 5% of the biopsy specimen in order to be 
considered (Ramon, 2007). Nevertheless, prostate cancer presents frequently with more 
than one histological pattern, so in order to reflect this heterogeneity, the two most 
common patterns have to be taken into account (Buhmeida et al., 2006; Eble et al., 2004). 
The final score attributed to the tumor consists on the sum of these two patterns, so the 
score is always between two and 10, the less and the more aggressive, respectively 
(Damber, 2008; Epstein, 2010). The two patterns and the final score are always reported 
(3+4=7, for example). Because grade one is unusual and grade two is frequently mixed 
with grade three, resulting in score five, some Gleason scores, like two, three and four are 
rarely attributed, making scores six and seven the two most common (Eble et al., 2004). 
3.4.2 Clinical and pathological staging  
PCa staging is used to describe the extent of the disease, in order to predict the 
clinical outcome, define treatment options, and evaluate the response to treatment (Cheng 
et al., 2012; Ramon, 2007). Staging of prostate cancer is challenging due to the 
complexity of the disease, so an accurate and uniform language is required. The most 
commonly used system for PCa staging is the tumor, node and metastasis (TNM) system 
of the American Joint Committee on Cancer/Union Internationale Contre le Cancer 
(AJCC/UICC) (Cheng et al., 2012; Edge and Compton, 2010). This classification system is 
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based on three parameters, which are the extent of the primary tumor (T), the presence of 
involved lymph nodes and its extent (N) and, lastly, the presence of distant metastases 
(M) (Edge and Compton, 2010; Ramon, 2007). 
TNM staging includes both clinical and pathological staging. The first is based on 
information obtained before the first treatment, and the assessment of the tumor extent is 
determined by TRUS, DRE and other imaging techniques. On the other side, pathological 
staging is accessed through histological examination of the tumor extent in the prostate 
gland and its surroundings, which can only be properly achieved after total radical 
prostatectomy (Cheng et al., 2012; Hoedemaeker et al., 2000). 
The TNM system was revised in 2010 (Table 3) and some changes have been 
made in the T3a category, with the incorporation of extraprostatic extension and 
microscopic bladder neck invasion. Other alterations include the recognition of the 
Gleason score as being the ideal grading system, and the inclusion of prognostic factors 
of Gleason score and preoperative PSA into stage grouping. There are four groups, 
represented in Table 4, in which a higher number indicates a worst prognosis (Cheng et 
al., 2012). 
Table 3 - AJCC clinical and pathological TNM classification of prostatic tumors [adapted from (Edge, 
2010)]. 
Primary tumor (T)  
CLINICAL 
TX – Primary tumor cannot be assessed 
T0 – No evidence of primary tumor 
T1 – Clinically unapparent tumor neither palpable nor visible by imaging 
T1a – Tumor incidental histological finding in 5% or less of tissue resected  
T1b – Tumor  incidental histological finding in more than 5% of tissue resected 
T1c – Tumor identified by needle biopsy (for example, because of elevated PSA) 
T2 – Tumor confined within prostate 
T2a – Tumor involves one-half of one lobe or less 
T2b – Tumor involves more than one-half of one lobe but not both lobes 
T2c – Tumor involves both lobes 
T3 – Tumor extends through the prostate capsule  
T3a – Extracapsular extension (unilateral or bilateral) 
T3b – Tumor invades seminal vesicle(s) 
T4 – Tumor is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
PATHOLOGIC (PT) 
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pT2 – Organ confined 
pT2a – Unilateral, one-half of one side or less 
pT2b – Unilateral, involving more than one-half of side but not both sides 
pT2c – Bilateral disease 
pT3 – Extraprostatic extension 
pT3a – Extraprostatic  extension or microscopic invasion of bladder neck 
pT3b – Seminal vesical invasion 
pT4 – Invasion of the rectum, levator muscles, and/or pelvic wall 
Regional Lymph Nodes (N)  
CLINICAL 
NX – Regional lymph nodes were not assessed  
N0 – No regional lymph node metastasis  
N1 – Metastasis in regional lymph node(s) 
PATHOLOGIC 
pNX – Regional nodes not sampled  
pN0 – No positive regional nodes 
pN1 – Metastases in regional node(s) 
Distant Metastasis (M)  
M0 – No distant metastasis 
M1 – Distant metastasis 
M1a – Nonregional lymph node(s) 
M1b – Bone(s) 
M1c – Other site(s) with or without bone disease 
 
Table 4 - AJCC stage grouping [adapted from (Edge, 2010)]. 
Group T N M PSA (ng/ml) 
Gleason 
score 
I 
T1a-c N0 M0 < 10 ≤ 6 
T2a N0 M0 < 10 ≤ 6 
T1-2a N0 M0 X X 
IIA 
T1a-c N0 M0 < 20 7 
T1a-c N0 M0 ≥ 10 and ≤ 20 ≤ 6 
T2a N0 M0 ≥ 10 and ≤ 20 ≤ 6 
T2a N0 M0 < 20 7 
T2b N0 M0 < 20 ≤ 7 
T2b N0 M0 X X 
IIB T2c N0 M0 Any PSA Any Gleason 
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T1-2 N0 M0 ≥ 20 Any Gleason 
T1-2 N0 M0 Any PSA ≥ 8 
III T3a-b N0 M0 Any PSA Any Gleason 
IV 
T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
 
*X: unknown. 
3.5 Treatment  
There are many treatment options available for PCa management and its choice 
relies on the stage and grade of the tumor at the time of diagnosis, patient´s age, 
comorbidities and personal believes (Heidenreich et al., 2011; Siegel et al., 2012). 
Currently, there is not enough information about what is the best treatment, since few 
prospective randomized trials comparing different treatment options have been done 
(Heidenreich et al., 2011; Ramon, 2007). The most common used treatments are 
represented in Figure 7, in function of age.  
 
*Initial treatment received.  
Figure 7 - Primary treatments for PCa, by age in 2008 [adapted from (Siegel et al., 2012)]. 
3.5.1 Active surveillance (AS) 
AS or watchful waiting consists in postponing the treatment until it is necessary 
(Heidenreich et al., 2008; Ramon, 2007). It was proposed as a form of reducing 
overtreatment in patients with low-risk of PCa progression. It is recommended in men at 
low-risk groups, with confined disease, Gleason score < 6, PSA levels < 10ng/ml and with 
a life expectancy > 10 years. These recommendations are due to the fact that men 
belonging to this risk group have a 20-year PCa-specific survival rate of 80 to 90% 
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(Heidenreich et al., 2011), however they should be monitored periodically with PSA testing 
and re-biopsies (Ramon, 2007).  
3.5.2 Radical prostatectomy (RP) 
RP constitutes the only treatment option with curative intent for localized PCa with 
a benefit in cancer-specific survival, when compared to watchful waiting (Damber, 2008; 
Heidenreich et al., 2011). In men with a normal erectile function and localized disease, 
normally a nerve-sparing approach is made. In men with intermediate and high-risk PCa, 
a pelvic lymphadenectomy should be performed, while for men with low-risk, its need and 
extent are still in debate. Neoadjuvant therapy with androgen deprivation has no value, 
since it does not improve overall survival (OS), and recommendations of adjuvant 
androgen deprivation therapy (ADT) after surgery, remain controversial. However, 
adjuvant radiation therapy after surgery showed to improve biological survival, OS and 15-
year metastasis-free survival (Heidenreich et al., 2011). 
3.5.3 Radiation Therapy  
Radiation therapy can be delivered using external-beam radiation or 
brachytherapy, or used in combination. They have emerged as alternatives for men with 
localized PCa, in whom RP is not recommended (Heidenreich et al., 2008). Both forms 
have a disease-free survival identical of RP, for patients with early-stage PCa (Damber, 
2008; Jani and Hellman, 2003). Dose-escalation radiotherapy can be used in these 
patients or can be combined with hormonal therapy (Damber, 2008). 
3.5.4 Hormonal therapy (androgen-deprivation) 
Since androgens are essential for PCa development and progression (Shen and 
Abate-Shen, 2010), hormonal therapy is the gold standard for patients with more 
advanced PCa. Testicular androgens can be eliminated through physical (surgical 
removal) or chemical castration. The latter can be accomplished with oestrogens that 
reduce the secretion of the gonadotropin-releasing-hormone (GnRH) in the hypothalamus; 
with the downregulation of GnRH receptors with agonists or antagonists, thus inhibiting 
the pituitary secretion of luteinising hormone (LH) or follicle-stimulating hormone (FSH); or 
with the administration of antiandrogens (Damber, 2008; Mottet et al., 2011). 
3.5.5 Chemotherapy 
Chemotherapy is indicated for the more advanced and metastatic PCa and mainly 
when androgen deprivation fails, and should be initiated early in order to improve survival. 
There are already some combination regimens with good results. The use of docetaxel in 
combination with prednisone seems to be the best treatment for these men when 
compared to mitoxantrone, with a survival benefit of approximately three months and a 
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better quality of life, with less morbidities (Mottet et al., 2011). Recently, a vaccine, 
Sipuleucel-T was approved by the Food and Drug Administration (FDA) and consists in an 
autologous cellular immunotherapy that contains autologous CD54+ cells, stimulating the 
immune system. Sipuleucel-T has proven to increase the OS in 4,1 months, however its 
concomitant use with chemotherapy and immunosuppressive drugs has not been studied 
yet (Mottet et al., 2011). 
3.6 Prostate Cancer Genetic Alterations 
Cancer is a pathology characterized by genetic alterations that can activate 
oncogenes or inactivate tumor suppressor genes (TSGs) (Porkka and Visakorpi, 2004). 
These can be inherited, thus predisposing to a higher cancer risk, or acquired during the 
progression of the disease. Therefore, PCa can be divided in two types: the familial type, 
in which the age at diagnosis is general below 55 years old; and sporadic, where the 
individual is exposed, at some point, to an external factor that damages his genetic 
material (Alvarez-Cubero et al., 2012; Porkka and Visakorpi, 2004).  
The genetic alterations associated with PCa that have been discovered so far are 
going to be explored in the following text. It is important to reinforce that although many 
genetic and epigenetic alterations are already known, the mechanisms underlying 
proliferation, differentiation and tumor progression in the prostatic gland await further 
exploitation (Jung et al., 2004a). 
3.6.1 Germline mutations and polymorphisms  
In order to identify potential genes responsible for familial PCa, many approaches 
have been used. The most classic approach is linkage analysis that identifies cancer 
susceptibility loci. In Table 5 the loci discovered so far are represented, together with the 
chromosomal position and its associated gene (Boyd et al., 2012). The most promising 
candidate genes for PCa are RNASEL, MSR1 and ELAC2, which have been described as 
hereditary TSG (Alvarez-Cubero et al., 2012). These genes are associated with the 
response to infections (Gonzalgo and Isaacs, 2003), and thus linked to the idea that PCa 
is somehow associated with inflammation.  
After the discover of BRCA1, in the 17q21 region, as a candidate gene for prostate 
cancer development, this chromossomal region was studied deeper (Boyd et al., 2012; 
Ewing et al., 2012). Consequently, in the beginning of 2012, Ewing et al. screened 
approximately 200 genes in this region and found a mutation, p.Gly84Glu (G84E to 
simplify), in another gene, HOXB13, which is a homeobox transcription factor implicated in 
the development of the normal prostate. More recently, genome wide association studies 
(GWAS) allowed the discover of many other susceptibility loci (Boyd et al., 2012). Some 
single nucleotide polymorphisms (SNPs) in genes associated with androgen synthesis 
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and metabolism, like the androgen receptor gene (AR), the SRD5A2 gene (encodes part 
of 5α-reductase), the CYP17A1 gene (encodes the cytochrome P450), among others, 
have also been associated with PCa development (Bosland and Mahmoud, 2011; Boyd et 
al., 2012; Damber, 2008; Deutsch et al., 2004).  
Altough many inherited genetic alterations have been described, the focus of 
research remains in high penetrant genes, such as BRCA1/2 and more recently HOXB13, 
as rare genomic variants may be used as biomarkers for the prediction of incidence, 
prognosis and response to therapy, or even be incorporated in clinical trials in a near 
future (Bambury and Gallagher, 2012). However, because they are rare, it has been 
suggested that low-penetrance gene polymorphisms might also contribute for PCa 
development. New technologies such as GWAS and SNP arrays are very important to 
identify variants that have a moderate effect on the risk of PCa development (Boyd et al., 
2012). 
Table 5 - PCa predisposition loci discovered by linkage analysis [adapted from (Boyd et al., 2012)]. 
 
 
3.6.2 Somatic gene alterations 
Somatic mutations  
Like in other malignancies, somatic mutations are relatively common in PCa, with 
the activation of oncogenes or the inactivation of TSGs (Boyd et al., 2012; Jung et al., 
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2004a). The mutated genes that have already been described are represented in Table 6 
(Boyd et al., 2012). Mutations in PTEN, a TSG involved in apoptosis, cell-cycle control 
and angiogenesis, are the most frequent. Loss of heterozygosity in 10q23 is also 
common, especially in metastatic lesions, which suggests that this TSG might be 
important for PCa progression (Boyd et al., 2012; Deutsch et al., 2004). TP53 is also a 
TSG, being the most frequently mutated gene in all human cancers, and its mutations are 
observed in 20 to 30% of advanced localized PCa tumors (Boyd et al., 2012; Porkka and 
Visakorpi, 2004). Other genes that are also mutated in some cases are RNASEL (13% of 
cases), EPHB2 (10% of cases), and, less frequently, mutations in RAS, CHK2, SPOP, 
EGFR, PLXNB1, FOXA1 and many others (Boyd et al., 2012; Porkka and Visakorpi, 
2004).  
Another gene that is worth to mention is the AR gene, since it codifies the receptor 
that mediates the androgen action in prostate cancer cells (Porkka and Visakorpi, 2004). 
Many somatic alterations in this gene have been described, although mutations in 
untreated PCa tumors are rare. On the other hand, they are frequently found in androgen-
refractory tumors after treatment with anti-androgens and androgen suppression, which 
implicates these mutations in the progression of the disease. Seventy missense mutations 
have already been identified in the AR gene (Boyd et al., 2012).  
Table 6 - PCa genes with somatic mutations [adapted from (Boyd et al., 2012)]. 
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Copy number alterations 
The two major techniques that allow the identification of copy number gains and 
losses are comparative genomic hybridization (CGH) and fluorescence in situ 
hybridization (FISH). The first one revealed that gains at 1q, 2p, 7, 8q and Xq and losses 
at 1p, 6q, 8p, 10q, 13q and 16q are the most common alterations in PCa at the 
chromosome level. Later on, FISH showed candidate genes for some of the alterations: 
gains of MYC (8q24) and AR (Xq12); and deletions of NKX3-1 (8p21), KLF6 (10p15), 
PTEN (10q23), P27/Kip1 (12p13) and KLF5 (13q21) (Boyd et al., 2012). NKX3-1 loss of 
expression is more common in advanced and refractory tumors (near 80%) and it is 
thought that the mechanism involved in the loss of the tumor suppressive activity is 
haploinsufficiency, since the other allele is not mutated (Jung et al., 2004a; Porkka and 
Visakorpi, 2004). 
Chromosomal rearrangements  
Genetic alterations such as chromosomal rearrangements are common in both 
hematological neoplasias and in solid tumors (Huang and Waknitz, 2009). The discovery 
of fusion genes in a high proportion of the prostate tumors had major importance to 
understand the molecular mechanisms involved in prostate carcinogenesis (Damber, 
2008). 
In 2005, Tomlins and his colleagues described chromosomal rearrangements 
where the gene TMPRSS2 (a serine protease produced in response to androgens in the 
epithelial cells) was fused to ERG or ETV1, two members of the ETS family of 
transcription factors. This fusion was reported to be present in 50% of the prostate 
cancers, making it the most prevalent fusion gene in any solid tumor. As a result of these 
fusions, the ETS gene is under the control of the TMPRSS2 promoter region and 
becomes overexpressed (Huang and Waknitz, 2009; Narod et al., 2008; Rubin et al., 
2011; Tomlins et al., 2005). 
Besides the TMPRSS2:ERG and TMPRSS2:ETV1 fusions, other ETS genes 
(ETV4, ETV5 and FLI1) were reported to be fused at the 5’ end with TMPRSS2 or other 5’ 
partners, being SLC45A3 (also an androgen-responsive gene) the second most frequent 
5´ partner rearranged with all the five ETS genes involved in PCa rearrangements (Boyd 
et al., 2012; Paulo et al., 2012a; Tomlins et al., 2009; Tomlins et al., 2007).  
Although the TMPRSS2:ERG fusion appears to be a key and early molecular 
event in PCa, it does not seem to be enough for the development of the disease. Some 
studies have associated this fusion with a more aggressive disease and it is known that 
ERG overexpression and PI3K signaling act together in the progression to advanced PCa. 
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There have been some efforts to apply these discoveries to diagnosis, prognosis and 
treatment, although more studies are needed (Rubin et al., 2011). 
3.7 Prostate Cancer Epigenetic Alterations 
Epigenetic alterations, unlike genetic alterations, do not affect the DNA sequence, 
but instead affect gene expression by mechanisms such as DNA methylation, histone 
modifications, chromatin remodeling and RNA interference. In the prostate, many genes 
have already been described to show abnormal methylation levels. Among these, 
RASSF1A and GSTP1 are worth to be mentioned (Gonzalgo and Isaacs, 2003). 
RASSF1A is found methylated in 60% to 70% of all PCa cases, being more common in 
tumors of higher grades (Gonzalgo and Isaacs, 2003). Hypermethylation of GSTP1 is the 
most frequent somatic gene alteration in PCa (Henrique and Jeronimo, 2004; Lin et al., 
2001) being considered an initiating event of prostatic carcinogenesis (De Marzo et al., 
2004; Gonzalgo and Isaacs, 2003; Nelson et al., 2001). It is silenced in almost every 
prostate carcinomas (90-95%) and in 70% of PIN lesions (Henrique and Jeronimo, 2004; 
Porkka and Visakorpi, 2004). GSTP1 is normally expressed in the basal cells, and 
encodes the π-class glutathione S-transferase (De Marzo et al., 2004; Nelson et al., 2003) 
that belongs to a family of detoxifying enzymes of different xenobiotics (Gonzalgo and 
Isaacs, 2003; Porkka and Visakorpi, 2004). GSTP1 is thought to act as a “caretaker” 
gene, since it is a scavanger of reactive oxygen species, and its inactivation may cause 
genome damage (De Marzo et al., 2004; Deutsch et al., 2004; Nelson et al., 2001). Since 
GSTP1 is so important for prostate carcinogenesis, restoring its expression and avoiding 
carcinogenic stress may be a good approach for cancer prevention (Nelson et al., 2001). 
3.8 The role of androgens 
It has long been assumed that androgens are somehow involved in prostate 
carcinogenesis, since both the prostate and PCa are androgen-dependent. Despite of a 
lack of enough epidemiological evidence, it seems that androgens have a different role in 
each step of the prostate carcinogenesis pathway. The oncogenic activity of androgens is 
related to their ability to stimulate cell growth, making the cells more prone for the 
accumulation of genetic alterations (Bosland and Mahmoud, 2011; Henderson and 
Feigelson, 2000).  
The binding of androgens to AR causes AR activation and translocation into the 
nucleus where it binds to specific DNA response elements on the promoter regions, 
interacting with other transcriptional factors and coregulators and activating the 
transcription of target genes. The hormone-receptor complex may act as break or 
accelerator of transcription. As AR plays a crucial role in the regulation of growth and 
differentiation of PCa, androgen deprivation therapy is a good option for patients with 
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metastatic PCa (Jung et al., 2004b; Kim et al., 2010a; Kim et al., 2010b). However, most 
of the patients relapse and develop androgen-independent (AI) cancers, where AR 
activation and signaling remain intact (Kim et al., 2010b; Shen and Abate-Shen, 2010).  
Several mechanisms were proposed for the retained activity of AR signaling in AI 
tumors. These include AR amplification that results in overexpression of AR and increases 
the sensitivity to low levels of androgens, thus promoting the growth of prostate cancer 
cells;  and AR mutations that alter the ligand-specificity of the receptor, allowing its binding 
and activation by nonandrogens and anti-androgens (De Marzo et al., 2004; Nelson et al., 
2003; Shen and Abate-Shen, 2010). 
4. Homeobox Genes  
The family of homeobox genes, first described in Drosophila melanogaster, 
comprises two subfamilies, class I (clustered homeobox genes – HOX) and class II 
(nonclustered or divergent) (Nunes et al., 2003). In terms of evolution, homeobox genes 
are highly conserved and arose by duplication from a single ancestral cluster (Daftary and 
Taylor, 2006; Lappin et al., 2006). HOX genes codify a family of transcription factors  
(Kelly et al., 2011; Kim et al., 2010b) with 39 members described in humans (Chen and 
Sukumar, 2003; Daftary and Taylor, 2006). They are organized in four different genomic 
clusters: A, B, C and D, each with 9 to 13 genes. The different clusters are located  in 
7p15, 17q21.2, 12q13 and 2q31, respectively, and comprise 13 paralog groups. The 
structure of HOX genes and the proteins encoded by them are represented in Figure 8. 
HOX genes are small, being composed of only two exons and one intron (Lappin et al., 
2006). Hox proteins are characterized by their homeobox domain, which is located in the 
second exon and is composed of a 183-bp sequence with 61 amino acids. The 
homeodomain is a helix-turn-helix-motif with DNA-binding activity, allowing the binding to 
specific regions and therefore activating or repressing target genes (Chen and Sukumar, 
2003; Daftary and Taylor, 2006; Kelly et al., 2011; Lappin et al., 2006). They harbor an 
acidic tail in the COOH extremity and a pentamer near the homeodomain, which is 
responsible for the binding of the TALE (three amino acid loop extension) proteins (Lappin 
et al., 2006).  
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Figure 8 - General structure of the HOX genes and their protein products [adapted from (Lappin et al., 
2006)]. 
HOX genes are very important regulators of the positional identity of the organs 
and tissues in the anterior-posterior axis during embryonic development, from the level of 
the hindbrain to the end of the spine (Daftary and Taylor, 2006; Jung et al., 2004a). They 
are known to regulate cell proliferation and differentiation during embryogenesis and 
organogenesis (Chen and Sukumar, 2003; Economides and Capecchi, 2003; McMullin et 
al., 2009), showing spatial and temporal colinearity. Their expression is tissue-specific and 
is related to the stage of development (Kim et al., 2010b; Krumlauf, 1994; McMullin et al., 
2009). Paralogs with lower numbers (3’ genes) are the first to be expressed and mainly in 
the anterior and proximal regions of the body axis, while 5’ genes are expressed in a later 
stage of the development and in the posterior and distal regions (Figure 9). This 
coordinated expression is commonly referred as the HOX code and it determines the 
phenotype of a nascent tissue (Daftary and Taylor, 2006; Ewing et al., 2012; Lappin et al., 
2006; McMullin et al., 2009). HOX genes exhibit functional redundancy, which means that 
a mutation or loss of expression in one gene can be compensated by the others (Lappin 
et al., 2006).  
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Figure 9 - Genomic organization of the mammalian HOX clusters and their embryonic expression 
pattern, which correlates with the chromosomal positioning [adapted from (Daftary and Taylor, 2006)]. 
HOX genes are very important for limb and pulmonary development in vertebrates, 
and many limb malformations and congenital lung abnormalities have already been 
associated with specific genes of this family (Lappin et al., 2006). They are also known for 
their involvement in the development of secondary sexual structures, like male accessory 
organs and female mammary glands (Jung et al., 2004a).  
Besides their part in embryogenesis and organogenesis, some HOX genes 
continue to be expressed in adult tissues that maintain developmental plasticity, mediating 
differentiation processes, homeostasis and organ functioning (Daftary and Taylor, 2006; 
Kelly et al., 2011). More recently deregulation of HOX expression patterns have been 
associated with many types of cancers (Cross and Burmester, 2008), such as prostate, 
breast, ovarian, endometrial, lung, renal, neuroblastoma, colorectal, leukemias and 
pancreatic, among others (Chen and Sukumar, 2003; Gray et al., 2011; Habel et al., 2013; 
Jung et al., 2005; Kelly et al., 2011; Zhao et al., 2005). HOX genes also exhibit tissue-
specificity in tumors, meaning that different tumors show a specific expression profile. The 
exact role of HOX genes is different depending on the type of malignancy, but it is known 
that they might interfere in different hallmarks of cancer (Chen and Sukumar, 2003; 
McMullin et al., 2009; Nunes et al., 2003). It has also been suggested that HOX genes 
that are expressed during embryonic development but show low or absent expression in 
adulthood can be overexpressed or re-expressed in neoplasias (Chen and Sukumar, 
2003; McMullin et al., 2009). 
4.1 HOXB13  
HOXB13 was first described by Zeltser and her colleagues in 1996, being the last 
discovered homeobox gene, and encodes the transcription factor HOXB13 (Zeltser et al., 
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1996). It belongs to the paralog group 13 and is located 70kb upstream of HOXB9. Its 
expression maintains the temporal and spatial colinearity typical of other HOX genes and 
is identical to other HOX-13 genes, being expressed in the urogenital sinus, posterior 
extent of the spinal cord and tailbud (Jung et al., 2004a; Jung et al., 2004b; Kim et al., 
2010b; Zeltser et al., 1996) and not being expressed in the genital tubercule or the limbs 
(Zeltser et al., 1996). 
HOX13 paralogs are particularly important for the prostate development, with 
HOXC13 being the only member of the group that is not expressed during embryogenesis 
(Economides and Capecchi, 2003; Jung et al., 2004b). Of these, HOXB13 paralog is the 
only that maintains a high expression level in adults, and its expression is confined to the 
prostate, distal colon and rectum (Figure 10) in an androgen-independent fashion (Ewing 
et al., 2012; Jung et al., 2004b; Sreenath et al., 1999; Zeltser et al., 1996). Interestingly, 
this contrasts with the expression pattern of NKX3.1, another androgen-dependent 
homeobox gene essential for prostate development (Bieberich et al., 1996; Sreenath et 
al., 1999). 
 
Figure 10 - Expression of HOXB13 in adult tissues using real time reverse transcription-PCR combined 
with Taqman probe [adapted from (Jung et al., 2004b)]. 
Economides and his co-workers demonstrated that mice with homozygous 
mutations leading to loss of function of HOXB13 have defects in the ventral prostate 
epithelium, malformations of the duct tips and an absence of secretory proteins such as 
p12 and p25. An overgrowth in all the major structures derived from the tail bud is also 
observed (Economides and Capecchi, 2003; Economides et al., 2003). These studies 
strengthen the importance of HOXB13 for the normal development of the prostate.  
4.1.1 HOXB13 and PCa 
Since HOXB13 is highly expressed in the prostate and its expression seems to be 
maintained in PCa (Edwards et al., 2005), multiple studies have tried to evaluate its 
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function in both the normal prostate and in prostate carcinogenesis (Ewing et al., 2012; 
Jung et al., 2004a; Jung et al., 2004b; Kim et al., 2010b). Despite its relevance for the 
development of the normal prostate already described (Economides and Capecchi, 2003; 
Huang et al., 2007; Norris et al., 2009), its exact function is not yet fully understood, 
specially what concerns prostate carcinogenesis. In fact, the role of HOXB13 in prostate 
cancer development remains highly controversial, since HOXB13 has been suggested to 
act both as an oncogene and as a TSG (Ewing et al., 2012; Jung et al., 2004a).  
However, it seems to be consistent that HOXB13 is only expressed in AR-
expressing cells and that its role is dependent on the cell type (Figure 11 and 12) and on 
the cellular environment (AR status and androgen stimulation) (Jung et al., 2004a; Jung et 
al., 2004b; Kim et al., 2010a; Kim et al., 2010b). Nevertheless, HOXB13 expression is not 
directly regulated by androgens (Jung et al., 2004a; Jung et al., 2004b; Sreenath et al., 
1999; Zeltser et al., 1996).  
 
Figure 11 - HOXB13 mRNA levels in the prostate (last column) and in ten prostate cell lines according 
to the status of the activity of the AR. P69, PrEc and Pz-HPV7 are benign prostate cell lines and the others 
are tumor-derived cell lines [adapted from (Jung et al., 2004b)]. 
 27 
 
 
Figure 12 - Protein levels of HOXB13 expression in seven prostatic cell lines by Western Blot (A) and 
immunocytochemistry (B) [adapted from (Kim et al., 2010b)]. 
In 2004, Jung et al. induced de novo expression of HOXB13 in the HOXB13-
negative and AR-negative PC-3 PCa cell line, and observed growth suppression along 
with alterations in cell morphology, typical of terminal differentiated cells. This effect was 
also evident in vivo, with a decrease in tumor volume five weeks after cell implantation. 
This growth inhibition was proved to result from cell cycle arrest at G1 phase caused by 
the down-regulation of cyclin D1, which is essential for accelerating this phase. The down-
regulation of cyclin D1 was shown to be caused by HOXB13 suppression of the β-
catenin/TCF-4 activity, since TCF-4 is an essential transcription factor of cyclin D1 
expression. This observation lead to the assumption that HOXB13 loss might represent a 
growth advantage for prostatic tumors (Jung et al., 2004a).  
The same group also studied the role of HOXB13 in the HOXB13-positive and AR-
positive LNCaP PCa cell line, demonstrating both by its overexpression and by its 
suppression, that HOXB13 plays different roles depending on the androgen stimuli (Jung 
et al., 2004b; Kim et al., 2010b). Briefly, when HOXB13 is overexpressed in the presence 
of androgens, it causes repression of androgen-activated AR transcriptional activity, by 
physically interacting with AR (Figure 13), modulating its positive growth signal and 
leading to an inhibition in cell growth (Kim et al., 2010a). On the other hand, in an 
androgen-free environment HOXB13 promotes cell proliferation through the inhibition of 
the TSG p21, allowing the activation of E2F mediated signaling (Figure 13) (Kim et al., 
2010b).  The same effect regarding the influence of androgens was observed when 
HOXB13 was suppressed in LNCaP cells, with the presence of R1881 conferring a stimuli 
for growth, and its absence inhibiting cell growth (Jung et al., 2004b; Kim et al., 2010a).  
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Regarding HOXB13 expression in PCa, there are still no certainties. A microarray 
study demonstrated that HOXB13 expression levels in PCa were higher than those found 
in normal adjacent tissue (Edwards et al., 2005), while others suggest that no such 
changes could be observed due to the heterogeneity and multifocal nature of PCa, or 
report a mixed pattern with HOXB13-positive and negative PCa cells  (Jung et al., 2004a; 
Kim et al., 2010a; Kim et al., 2010b). Nevertheless, it was demonstrated that hormone-
refractory tumors overexpress HOXB13 when compared to androgen-dependent 
carcinomas (Figure 14) (Kim et al., 2010b). 
 
Figure 13 - Proposed models of HOXB13 dual activity in the presence (A) and in the absence (B) of 
androgens. In the presence of androgens HOXB13 can either sequester AR coactivators or recruit more 
corepressors, thus inhibiting the AR-mediating growth signals. In the absence of androgens HOXB13 inhibits 
the TSG p21 leading to the activation of the cyclin dependent kinase 2 (CDK2), which together with the 
hyperphosphorylated RB releases the transcription factor E2F that activates the transcription of genes 
promoting cell proliferation [adapted from (Kim et al., 2010a; Kim et al., 2010b)]. 
 
Figure 14 - HOXB13 expression in androgen-dependent (AD) and androgen-independent (AI) tumors 
[adapted from (Kim et al., 2010b)]. 
4.1.2 HOXB13 mutations and PCa risk 
As mentioned before, at the beginning of 2012, Ewing and his colleagues (Ewing 
et al., 2012) screened more than 200 genes in the 17q21-22 region, a region that had 
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previously been suggested as a possible location for a PCa susceptibility gene, by linkage 
studies (Cropp et al., 2011; Lange et al., 2007; Lynch and Shaw, 2013). By sequencing 
germline DNA from patients and controls, they found a recurrent, albeit rare, mutation in 
HOXB13, G84E, now identified as rs138213197, in men of European descent, which co-
segregated with the disease in families. The G84E mutation leads to a change of an 
adenosine for a guanine in the second position of codon 84, causing a nonconservative 
substitution of glutamic acid for glycine. This mutation is localized in the first MEIS 
(myeloid ecotropic insertion site) interacting domain (Figure 15), which is a highly 
conserved domain that is thought to fine-tune HOX function by mediating the binding to 
members of the MEIS homeobox protein family, which act as HOX cofactors (Ewing et al., 
2012; Witte et al., 2013). 
The G84E mutation is found in 0.1% of the general population while in PCa 
patients it reaches 1.4% and it increases to 3.1% in patients with early-onset of the 
disease (≤55 years old) and with a positive family history (Ewing et al., 2012). This 
increase in strength of association was also corroborated by other studies, but no 
differences were found in Gleason grade between carriers and noncarriers (Akbari et al., 
2012; Karlsson et al., 2012; Kluzniak et al., 2013; Witte et al., 2013). Accordingly to 
Ewing, the location of the mutation might be the explanation for how prostate 
carcinogenesis is promoted and its nature indicates a role of HOXB13 more compatible 
with an oncogene than a TSG. It is important to note that G84E carriers do not lose the 
mutated allele, neither the expression of HOXB13, and that the mutated allele (A) is more 
frequently transmitted from parents to the affected offspring than the normal allele (G) 
(Ewing et al., 2012; Xu et al., 2013).  
Other groups have confirmed the association of the G84E germline mutation with a 
significantly increased risk of familial prostate cancer, although with lower frequency rates 
(Akbari et al., 2012; Breyer et al., 2012; Chen and Sukumar, 2003; Karlsson et al., 2012; 
Kluzniak et al., 2013; Laitinen et al., 2013; MacInnis et al., 2013; Schroeck et al., 2013; 
Stott-Miller et al., 2013; Witte et al., 2013; Xu et al., 2013). Haplotype studies have 
revealed that it is a founder mutation, more common in individuals of European descent, 
being more frequent in the Nordic countries than in North America and Australia (Karlsson 
et al., 2012; Xu et al., 2013). These studies also suggest that this mutation probably has 
occurred in Northern Europe (Chen et al., 2013). 
Although G84E variant only accounts for a small fraction of PCa cases, it confers a 
significantly increased risk of hereditary prostate cancer (Ewing et al., 2012; Lynch and 
Shaw, 2013), being the first major genetic mutation associated with familial PCa (Bessede 
and Patard, 2012; Karlsson et al., 2012).  
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Ewing et al., also found four additional missense variants, although much rarer 
than G84E, and these are shown in Figure 15. The p.Arg229Gly (R229G) was found in 
one patient from an African-American family and in his two brothers with PCa, and 
p.Gly216Cys (G216C) was found in two half-brothers with PCa, from an African-
Caribbean family. The p.Tyr88Asp (Y88D) and p.Leu144Pro (L144P) were found in 
LAPC4 and LNCaP cell lines, respectively, both PCa-derived and androgen-dependent. 
All of the mutations were predicted to affect protein structure and function (Ewing et al., 
2012).  
 
 
Figure 15 - Location of all the missense mutations found in HOXB13 by Ewing and collaborators 
[adapted from (Ewing et al., 2012)]. 
With the intent of addressing the association of HOXB13 mutations with PCa in the 
Chinese population, Lin et al. found a novel nonsynonymous mutation, p.Gly135Glu 
(G135E), resulting in the substitution of a glycine to a glutamic acid. It also appears to be 
a founder mutation that is associated with an increased risk of PCa in Chinese men. In 
contrast with the G84E mutation, this variant is located in the second MEIS interacting 
domain that is also a highly conserved domain (Lin et al., 2013). 
The fact that other variants besides G84E had also been found, reinforces the idea 
of the involvement of HOXB13 in prostate carcinogenesis, which is now established as a 
PCa susceptibility gene, with a relative risk of approximately 20 for carriers of the G84E 
mutation, and with a moderate penetrance in the average population (Ewing et al., 2012; 
Karlsson et al., 2012; Kluzniak et al., 2013). However, the utility of these discoveries need 
to be translated into the clinics, in order to identify men at higher risk which could benefit 
from early screening (Xu et al., 2013). It is also important to further explore the biological 
consequences of this variant and to evaluate how confined it is to prostate carcinogenesis 
(Kluzniak et al., 2013; Schroeck et al., 2013). 
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Given the recent discovery that germline mutations in the HOXB13 gene confer an 
increased risk for familial PCa, the main goal of this Master Thesis´s project was to search 
for somatic mutations and expression alterations of the HOXB13 gene in prostate 
cancer. Therefore, the specific goals of this project were: 
 To search for mutations in the entire coding sequence of the HOXB13 
gene in a series of primary tumor samples from patients with clinically 
localized PCa; 
 To evaluate the oncogenic potential of specific mutations in prostate 
carcinogenesis using in vitro models; 
 To compare HOXB13 mRNA expression levels in normal prostate tissues 
and in different molecular subtypes of prostate carcinomas. 
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1. Search for somatic mutations in HOXB13  
Since some germline mutations in HOXB13 gene have already been found in PCa 
patients and demonstrated to confer a higher risk for the disease (Chen et al., 2013; 
Ewing et al., 2012; Kluzniak et al., 2013; Lin et al., 2013; Lynch and Shaw, 2013; Witte et 
al., 2013; Xu et al., 2013), we have decided to start by searching somatic mutations in this 
gene. In order to accomplish this goal, the chosen strategy was DNA sequencing of the 
entire coding region of the gene.  
1.1 Samples  
To search for somatic mutations in HOXB13, a retrospective analysis was 
performed in primary tumor samples that had been collected from 200 patients with 
clinically localized PCa, diagnosed and treated with radical prostatectomy at the 
Portuguese Oncology Institute (Porto, Portugal) between 2001 and 2006. The patients 
were diagnosed at a mean age of 62 years (lower age of 49 years and highest age of 75 
years), with mean PSA levels and Gleason scores of 9.07 and 6.77, respectively. Of the 
initial series, only 178 cases were further analyzed, due to problems of quality of some of 
the samples.  
The LNCaP, PNT2, 22Rv1 and NCI-H660 prostate cell lines were also sequenced. 
DNA from the patient samples had previously been extracted by our group using 
the phenol-chlorophorm method using phase-lock gel (5 PRIME, Hamburg, Germany) and 
DNA from the prostate cell lines was extracted using the illustra TriplePrep kit (GE 
Healthcare, Life Sciences, Cleveland, USA), accordingly to the manufacturer´s 
instructions. 
1.2 Sanger sequencing 
Since HOXB13 gene has 855bp, it was necessary to perform the sequencing in 
separate, for the two exons. The primers for amplification of coding regions of the two 
exons were designed using the Primer-BLAST design tool and their specificity was 
evaluated with the Nucleotide Basic Local Alignment Search Tool (BLASTn) from the 
National Center for Biotechnology Information (NCBI), and were acquired from Metabion 
(Martinsried, Germany). The targeted region was amplified in two amplicons and the 
respective primer sequences are represented in Table 7. 
Table 7 – Primers´ sequences used for sequencing the HOXB13 gene (NM_006361.5). 
 
Primer forward sequence Primer reverse sequence 
Exon 1 5´-CGAGCTGGGAGCGATTTA-3´ 5´-AGCTCCAAGTCTCCCTCCTC-3´ 
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Exon 2  5´-TTGCACGTGCGCCTGTAGGG-3´ 5´-GTCTCCCCAGGACACCCCCA-3´ 
 
For the amplification reaction, a total volume of 30μl was used, with 1xTaq Buffer 
with (NH4)2SO4 (Thermo Fisher Scientific, Rockford, USA), 2.5mM MgCl2 (Thermo Fisher 
Scientific), 250mM dNTP mix (Thermo Fisher Scientific), 0.5M of each primer, 0.05U of 
Taq DNA Polymerase (Thermo Fisher Scientific) and 100 to 500ng of DNA. The PCR 
reaction was performed in the thermocycler with an initial step of denaturation at 94ºC for 
10 minutes; followed by five cycles with denaturation at 94ºC for 1 minute, annealing at 
64ºC for 1 minute, and extension at 72ºC for 2 minutes; and five identical cycles with a 
lower annealing temperature (62ºC). A third round of amplification included 25 cycles with 
another annealing temperature (60ºC) and the reaction ended with a final extension step 
at 72ºC for 7 minutes. The amplification was confirmed by electrophoresis in a 2% (w/v) 
agarose gel stained with ethidium bromide. 
 Next, the PCR product was purified using a mix of two enzymes from Thermo 
Fisher Scientific: exonuclease I (20μg/μl) and Fast Thermosensitive Alkaline Phosphatase 
(1μg/μl), in a proportion of 1:2. The purification was carried out in the thermocycler at 37ºC 
for 30 minutes for proper enzyme activity, followed by 15 minutes at 85ºC, to inactivate 
enzymes. For this reaction, 1μl of the mix (ExoSap) is added to 10μl of PCR product. This 
allows the removal of unincorporated primers and also degrades the nucleotides that have 
not been incorporated, thus the resulting PCR product is completely cleaned-up for 
sequencing (Werle et al., 1994).  
For the sequencing reaction, we only used the forward primers and the DNA 
amplicons were sequenced using the the BigDye® Terminator v3.1 Cycle Sequencing Kit 
from Applied Biosystems® (Life Technologies). The reaction consisted on mixing 1.9μl of 
sequencing buffer, 1μl of Terminator Ready Reaction Mix, containing dNTPs, ddNTPs-
fluorocromes, MgCl2 and Tris-HCl buffer, 3.5M of the already mentioned primers and 
lastly, 100 to 500ng of DNA, with a final reaction volume of 10μl. The PCR program at the 
thermocycler consisted on an initial denaturation step at 96ºC for 10 minutes, followed by 
35 cycles of denaturation at 96ºC for 10 seconds, annealing at 52ºC for 5 seconds and 
extension at 60ºC for 6 minutes. In order to reduce possible contaminants, the sequencing 
product was purified with IIlustra Sephadex® G-50 fine columns (GE Healthcare, Life 
Sciences, Cleveland, USA), according to the manufacturer´s instructions. Finally, to 
stabilize the DNA, the samples were eluted in 12μl of deionized formamide (Applied 
Biosystems). The sequencing was performed on a 3500 Genetic Analyzer (Applied 
Biosystems) and all the sequences were compared with the HOXB13 RefSeq sequence 
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(NM_006361.5) for variant detection, using the Mutation Surveyor V4.0.7 software 
(Softgenetics, State College, PA, USA). 
2. Cell Lines and Cell Culture 
Seven PCa cell lines, namely VCaP, NCI-H660, PC-3, 22Rv1, LNCaP, MDA-PCa-
2b and DU145 and one non-malignant prostatic cell line, PNT2, were grown in a 37ºC 
environment with 5% CO2 and were frequently tested for contaminations with Mycoplasma 
spp., using the PCR Mycoplasma Detection Set, from Clontech Laboratories (Mountain 
View, CA, USA).  
All the cell lines except MDA-PCa-2b were grown in media from GIBCO® 
(Invitrogen, Carlsbad, CA, USA). 22Rv1, LNCaP, PNT2 and DU145 were grown in RPMI-
1640 medium; VCaP in DMEM medium and PC-3 in F-12. All the media were 
supplemented with 10% Fetal Bovine Serum – FBS (GIBCO®) – with 1% 
Penicillin/Streptomycin (GIBCO®) at a final concentration of 1%. NCI-H660 was grown in 
RPMI-1640 medium supplemented with 1x Insulin-transferrin-selenium, 10nM of β-
estradiol, 10nM of hydrocortisone, 1x L-glutamine, and also FBS and 
Penicillin/Streptomycin at a final concentration of 5% and 1%, respectively. MDA-PCa-2b 
was grown in BRFF medium (Gentaur, Kampenhout, Belgium) supplemented with 20% 
FBS and 1% Penicillin/Streptomycin. 
VCaP and PNT2 were acquired from ECACC (European Collection of Cell 
Cultures), PC-3, DU145 and LNCaP from the Leibniz Institute DSMZ (German Collection 
of Microorganisms and Cell Cultures), NCI-H660 and MDA-PCa-2b from ATCC (American 
Type Culture Collection) and 22Rv1 were kindly provided by Dr. David Sidransky from 
Johns Hopkins University.  
The main features of the prostatic cell lines are summarized in Table 8. 
Table 8 – Principal characteristics of the eight prostate cell lines [adapted from the ATCC website 
available at http://www.atcc.org/]. 
Cell line 
Cell type 
(ATCC) 
Origin (ATCC) 
Androgen 
response 
PSA 
expression 
ETS 
rearrangements 
PNT2  
Epithelial; 
adherent  
Established by 
immortalization of 
normal adult 
prostatic epithelial 
cells. The primary 
culture was 
obtained from a 
  - 
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prostate of a 33 
year-old male post 
mortem (Berthon et 
al., 1995). 
22Rv1 
Carcinoma
; epithelial; 
adherent 
Derived from a 
xenograft that was 
serially propagated 
in mice after 
castration-induced 
regression and 
relapse of the 
parental, androgen-
dependent CWR22 
xenograft (Knouf et 
al., 2009; 
Sramkoski et al., 
1999). 
+ + - 
DU145 
Carcinoma
; epithelial; 
adherent 
Derived from a 
brain metastasis of 
a 69 year- old 
Caucasian male. 
- - - 
PC3 
Grade IV, 
adenocarci
noma; 
epithelial; 
adherent 
Initiated from a 
bone metastasis of 
a grade IV prostatic 
adenocarcinoma 
from a 62 year-old 
Caucasian male. 
- - - 
MDA-
PCa-2b 
Adenocarci
noma 
epithelial; 
adherent 
Established from a 
bone metastasis of 
a 63 year-old black 
male with 
androgen-
independent 
adenocarcinoma of 
the prostate. 
+ + 
MIPOL1-ETV1 
(Tomlins et al., 
2007) 
 
LNCaP 
Carcinoma 
epithelial; 
adherent, 
single cells 
and loosely 
attached 
clusters 
Derived from a left 
supraclavicular 
lymph node 
metastasis of a 50 
year-old Caucasian 
male. 
+ + 
 
Cryptic insertion of 
ETV1 into an 
intronic sequence 
from the MIPOL1 
locus at 14q13.3–
14q21.1 (Tomlins et 
al., 2007). 
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VCaP 
Epithelial; 
adherent 
Established in from 
a vertebral bone 
metastasis from a 
59 year-old 
Caucasian male 
with hormone 
refractory prostate 
cancer. 
+ + 
TMPRSS2:ERG 
(Narod et al., 2008). 
NCI-H660 
Epithelial 
neuroendo
crine; 
floating 
and 
attached 
clusters 
Derived from a 
lymph node 
metastasis of a 
small cell 
carcinoma, stage E. 
- - 
TMPRSS2:ERG 
(Mertz et al., 2007) 
 
3. Induction of de novo overexpression of HOXB13 in prostate 
cell lines 
In order to evaluate the oncogenic potential of the G84E mutation first described 
by Ewing (Ewing et al., 2012) and of the p.Ala128Asp (A128D, to simplify) mutation 
discovered along this work, we aimed to establish a cell model of prostate tumors 
harboring these mutations by transfecting prostate-derived cell lines with different 
expression vectors: HOXB13 wild-type, HOXB13 with the two mutations and a control 
vector. With these in vitro models, we expect to clarify if the overexpression of HOXB13 
and its mutated forms results in an oncogenic phenotype. 
3.1 Selection of the study cell model 
In order to choose the prostate-derived cell lines to induce HOXB13 
overexpression, some criteria had to meet. Since we have decided to study the role of 
HOXB13 both in the benign and in the malign contexts, we selected one of each kind. 
The first criterion was the absence of HOXB13 mutations and, accordingly to the 
literature, of the eight prostate-cancer cell lines already sequenced (LNCaP, PC3, DU145, 
22Rv1, E006AA, VCaP, MDA-PCa-2b, and LAPC4), only LNCaP and LAPC4 were found 
to harbor nonsynonymous mutations in this gene (Ewing et al., 2012), so they were 
excluded. Other prostate-derived cell lines were also sequenced, and the results will be 
presented later.  
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For the malignant context, we also intended to choose a cell line that is androgen-
responsive, which could then be an interesting model to study the influence of androgens 
in HOXB13´s biological role. We also decided to choose a PCa-derived cell line without 
known ETS rearrangements, since we are not certain that these rearrangements would 
not interfere with HOXB13 expression.  
Another condition was that the chosen cell lines would have low or basal level 
expression of HOXB13 and, according to the literature, we could choose DU145, PC3, 
22Rv1, P69, PrEc and Pz-HPV7 (Jung et al., 2004b; Kim et al., 2010a). However, we also 
evaluated HOXB13 expression both at the RNA and at the protein level, by quantitative 
real-time reverse transcription PCR (qRT-PCR) and immunoblotting, respectively. 
To meet all these criteria, and after obtaining our own results (shown later), the 
chosen cell lines were PNT2 and 22Rv1. 
3.1.1 RNA and protein extraction from prostate cell lines 
RNA from all the prostate cell lines available at the Cancer Genetics Department 
of IPO-Porto, which included PNT2, 22Rv1, DU145, PC-3, MDA-PCa-2b, LNCaP, VCaP 
and NCI-H660, had already been extracted by our group, using the TRIzol® Reagent 
(Ambion®, Life Technologies, Carlsbad, CA, USA). 
RNA from sub-confluent 22Rv1- and PNT2-derived cell populations (transfected 
cell lines) was extracted using the TRIzol® Reagent. First the samples were homogenized 
with 500µl of TRIzol, which lyses cells and dissolves its components. Then, 100µl of 
chloroform were added, to separate phases, and RNA was precipitated with 250µl of 
100% isopropanol. Finally, the RNA was washed with 250µl of 75% ethanol and 
ressuspended in 25µl of RNase-free water. RNA concentrations and purity were 
measured in a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). 
Protein extracts from the eight prostatic cell lines were also available and had 
been obtained using RIPA lysis buffer (Santa Cruz Biotechnology, CA, USA).  The same 
extraction method was used for protein extraction of 22Rv1- and PNT2-derived cell 
populations. Concisely, sub-confluent cells were washed twice with PBS and 150µl of 
RIPA were added. The flasks were scraped and the cell lysate was set on ice for 30 
minutes, followed by centrifugation at 180rcf for 30 minutes at 4ºC in order to obtain the 
protein extract. For the measurement of protein concentrations, the Thermo 
Scientific™Pierce™BCA Protein Assay (Rockford, USA) was used. The assay consists on 
a colorimetric detection, based on the reduction of Cu+2 to Cu+1 by protein in an alkaline 
medium, which results in a purple-colored product due to the chelation of two molecules of 
bicinchoninic acid (BCA) with the Cu+1. The reaction consisted on mixing 200µl of the BCA 
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solution with 25µl of each sample of unknown concentration, followed by a period of 
incubation at 37ºC for 30 minutes. The absorbance was then read at a wavelength of 
562nm in the FLUOstar Omega microplate reader (BMG Labtech). Protein quantification 
was achieved using the standard curve method, in which a curve is built using a series of 
known consecutive dilutions of BSA (bovine serum albumin). For these controls, the 
reaction was exactly the same as described for the samples.  
3.1.2 Complementary DNA (cDNA) synthesis 
RNA from the prostatic cell lines had already been converted into cDNA using the 
TransPlex Whole Transcriptome Amplification Kit (Sigma-Aldrich, Steinheim, Germany). 
For 22Rv1- and PNT2-derived cell populations, cDNA was synthetized using the 
RevertAid H Minus First Strand cDNA Synthesis Kit from Thermo Scientific. Briefly, 1µg of 
template RNA was mixed with 1µl of oligo (dT)18 primer in a total reaction volume of 12µl, 
incubated at 65ºC for 5 minutes and chilled on ice for 2 minutes. Then, 8µl of a mix 
containing 1xReaction Buffer, 20U of RiboLock RNase Inhibitor, 1mM of dNTP Mix and 
200U of RevertAid H Minus M-MuLV Reverse Transcriptase in a final volume of 20µl, 
were added. The reaction took place at 42ºC for 60 minutes, followed by enzyme 
inactivation at 70ºC for 5 minutes.  
3.1.3 Quantitative reverse transcription PCR (qRT-PCR) 
In order to evaluate HOXB13 expression at the RNA level, quantitative real-time 
reverse transcription PCR was performed. HOXB13 relative expression levels were 
evaluated in the eight available prostatic cell lines, as well as in the 22Rv1- and PNT2-
derived cell populations.  
HOXB13 primers and probe were designed using the Primer3 software (v.0.4.0) 
(Untergrasser A, 2012 ) using the criteria of the Primer Express® Software for Real-Time 
PCR version 3.0 (Applied Biosystems), and its specificity was evaluated with the BLASTn. 
Both primers and probe were purchased from Metabion. The primers’ sequences were 5´- 
GTTGCCAGGGAGAACAGAAC-3´ (forward) and 5´-TGTACGGAATGCGTTTCTTG-3´ 
(reverse). The probe used was a TaqMan® probe, that is a dual labeled fluorogenic probe 
and its sequence was 5´-AAGGCAGCATTTGCAGACTCCAGC-3´. The probe has a FAM 
fluorophore linked to the 5´ end and a quencher dye (TAMRA) at the 3´ end. The principle 
of TaqMan® probes is represented in Figure 16.  
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Figure 16 - TaqMan probe principle. A – During the annealing step, both the primers and the probe anneal 
with the template and due to the proximity of the quencher and the fluorophore, fluorescence is strongly 
reduced. B- At the extension step, Taq DNA polymerase extends the primer and when it reaches the probe, it 
cleaves the fluorophore (5´ 3´ exonuclease activity), releasing it from the quencher inhibition, so the 
fluorescence can be measured. The emitted signal is then measured and is proportional to the amount of 
accumulated PCR product [Adapted from Critical factors for successful Real-time PCR (2010) available at the 
Qiagen´s website]. 
The reactions were run in 96-well plates on the Applied Biosystems 7500 Real-
time PCR system (Applied Biosystems). Reactions were performed in triplicate and for 
each reaction 2µl of cDNA were mixed with 0.373µM of each primer, 0.25µM of the dual 
labeled probe, 1xSensiFASTTMProbe Lo-ROX mastermix (BIOLINE, London, UK) and 
nuclease-free water for a final reaction volume of 20µl. The reactions were performed 
using the following conditions: 50ºC for 2 minutes and 95ºC for 10 min, followed by 45 
cycles at 95ºC for 15 seconds and 60ºC for 1 minute.  
For the analysis, HOXB13 expression levels were normalized to the expression of 
a housekeeping gene, Beta glucuronidase (GUSB), in order to normalize differences in 
RNA input. The primers for this housekeeping gene were acquired from Applied 
Biosystems as a predesigned TaqMan® Endogenous Control. A standard curve was built 
using five consecutive ten-fold dilutions of a positive control template (DNA from the 
LNCaP cell line) to determine amplification efficiencies of both the target and the 
endogenous reference gene. 
For the quantification of HOXB13 relative expression levels in the eight prostatic 
cell lines, the comparative threshold cycle (Ct) method was used, in which a ∆Ct value is 
calculated and describes the difference between the Ct of the target gene (HOXB13) and 
the Ct of the housekeeping gene (GUSB). The Ct (from cycle threshold) is inversely 
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proportional to the initial copy number and it represents the cycle at which the 
amplification plot crosses the threshold value, where there is a significantly increase in 
fluorescence. 
For the 22Rv1- and PNT2-derived cell populations, the ∆∆Ct method was used, in 
which the relative expression levels of all samples were normalized for the levels of the 
cells transfected with the control vector (p-Entry). This value was calculated by subtracting 
the average ∆Ct of the reference sample to the sample of interest. 
3.1.4 Immunoblotting  
Immunoblotting is a technique that uses antibodies to identify specific proteins 
among a number of unrelated protein species, in a given sample. Briefly, proteins are 
separated by electrophoresis and transferred to membranes that are incubated with a 
specific primary antibody, followed by incubation with a labeled secondary antibody 
(Figure 17) (Magi and Liberatori, 2005).  
To separate protein extracts, a 10% SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed. First, 30µg of protein extract from each prostate cell line 
were mixed with 5x loading buffer (0.5M Tris-HCl - pH 6.8, 2% SDS, 10% glycerol and 
0.05% bromophenol blue) and incubated at 95ºC for 5 minutes to denature proteins. 
Then, 20µl of each sample were loaded in the 10% gel and were run at 120V/cm. After the 
electrophoresis, the proteins were transferred to a 0.1µm nitrocellulose membrane 
(Sigma-Aldrich) and for that, a “sandwich” consisting on the nitrocellulose membrane, the 
gel, sponges and filter paper (all pre-wet in 1x Tris-Glycine buffer with 20% methanol) was 
assembled. The transfer was run at 50V/cm for 1 hour. The membrane was blocked in a 
blocking solution (5% non-fat-dry milk in TBS-0.1% Tween 20) for 1 hour, and incubated 
overnight (4ºC, under agitation) with the Anti-HOXB13 antibody (Abcam, Cambridge, MA, 
USA) diluted in blocking solution (1:1000). In the following day, the membrane was 
washed four times (10 minutes each) with TBS-0.1% Tween 20, and incubated for 1 hour 
at room temperature with the secondary antibody, goat anti-rabbit IgG (1:100000) from 
Santa Cruz Biotechnology. This antibody is linked to a reporter enzyme, the horseradish 
peroxidase (HRP), allowing the detection of the HOXB13 protein. The membrane was 
washed again before proceeding to chemiluminescence detection. For 
chemiluminescence detection, the Immun-Star™ WesternC™ kit (Bio-Rad, Munich, 
Germany) was used and the specific bands were visualized by autoradiography.  
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Figure 17 - Immunoblotting procedure. Proteins are separated by gel electrophoresis according to their 
molecular weight and transferred to a nitrocellulose membrane by electroblotting. The membrane is then 
incubated with specific antibodies, and detection is performed by autoradiography [adapted from 
http://www.bio.davidson.edu/genomics/method/Westernblot.html]. 
3.2 Construction of the HOXB13 expression vectors 
An HOXB13 expression vector was purchased from Origene (Rockville, MD, USA) 
and is represented in Figure 18. This vector has the particularity of having a Myc-DDK tag 
fused at the C-terminal of the ORF, which allows easy purification and antibody detection 
using the 4C5-AntiDDK monoclonal antibody (Origene). The selection antibiotic for this 
vector is kanamycin, at a final concentration of 25µg/ml.  
 
Figure 18 - Plasmid map of the Myc-DDK-tagged ORF clone of Homo sapiens homeobox B13 
(HOXB13) as transfection-ready DNA [adapted from the Origene website, available at 
www.origene.com/orf_clone/trueclone/NM_006361/RC209991/HOXB13.aspx]. 
The HOXB13 plasmid was expanded in Stellar™ Competent Cells from Clontech 
Laboratories. To do such, 25µl of competent cells were mixed with 0.05ng of the plasmid 
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in a 14-ml round-bottom tube and then placed on ice for 30 minutes. The cells were 
exposed to a heat shock at 42ºC for 45 seconds and again placed on ice for 2 minutes. 
SOC medium (Clontech Laboratories), previously warmed, was added and the mix was 
incubated by shaking for 1 hour at 37ºC. 2.5ng of a control vector, pUC18 (Origene), were 
transformed in parallel to evaluate the efficiency of the transformation. 100µl of the 
transformed culture were plated in selective medium: Luria-Bertani (LB) agar with 25µg/ml 
of kanamycin (Sigma-Aldrich) for the HOXB13 plasmid, and LB agar with 50µg/ml of 
ampicillin (GIBCO®) for the pUC18 control, and incubated overnight at 37ºC. The solid 
medium was made by mixing 1% (w/v) Bacto™ Agar with 1% (w/v) Bacto™ Tryptone, 
0.5% (w/v) Bacto™ Yeast Extract (all from Becton, Dickinson and Company, Sparks, MD, 
USA) and 0.25% (w/v) sodium chloride.  
To create the mutated vectors (G84E and A128D), mutagenesis was induced in 
the wild-type HOXB13 vector, using the QuikChange II Site-Directed Mutagenesis Kit 
(Figure 19) from Agilent Technologies (Santa Clara, CA, USA). This technique allows site-
specific mutations in double-stranded plasmids and is expected to generate mutants with 
an efficiency >80%. First, two sets of oligonucleotide primers were designed using the 
Quick-Change Primer Design Program (Agilent Technologies) to create the desired 
mutations, and were acquired from Sigma-Aldrich. The primers sequences were the 
following: 
 A128D Forward: 5’-CGCCCCACTGAGTTTGACTTCTATCCGGG-3’ 
 A128D Reverse: 5’-CCCGGATAGAAGTCAAACTCAGTGGGGCG-3’ 
 G84E Forward: 5’-GGTTACTTTGAAGGCGGGTACTACTCCTGCC-3’ 
 G84E Reverse: 5’-GGCAGGAGTAGTACCCGCCTTCAAAGTAACC-3’ 
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Figure 19 - Three-step procedure of the Site-Directed Mutagenesis method [adapted from the Instruction 
manual of the QuikChange II Site-Directed Mutagenesis Kit, available at 
http://www.chem.agilent.com/Library/usermanuals/Public/200523.pdf]. 
The first step consisted on the mutant strand synthesis, using the HOXB13 vector 
and the two sets of oligonucleotide primers for the desired mutations. The primers were 
extended in the thermocycler by the PfuUltra High fidelity DNA polymerase, thus 
generating a mutated plasmid, with staggered nicks. This enzyme has the particular 
feature of having an 18-fold higher fidelity in DNA synthesis than the regular Taq DNA 
polymerase, thus avoiding unwanted errors during the process. For the mutant strand 
synthesis reactions, 50ng of dsDNA template were used, with 125ng of each primer, 
1xreaction buffer, 1µl of dNTP mix, and 0.05U of PfuUltra High fidelity DNA polymerase in 
a final reaction volume of 50µl in double-distilled water (ddH2O). Two different reactions 
were performed, one for each mutation. Besides the two mutant strand synthesis 
reactions, an additional reaction was done, to evaluate the mutagenesis efficiency 
according to the manufacturer´s instructions. Briefly, a pWhitescript 4.5-kb control plasmid 
(Agilent Technologies) was used, which contains a stop codon in the β-galactosidase 
gene, instead of a glutamine. Using the oligonucleotides provided by the manufacturer, 
the mutagenesis reaction will reverse the stop codon into the original glutamine codon, 
creating a point mutation in the plasmid that will allow the expression of full-length β- 
galactosidase. Therefore it allows distinguishing the colonies with and without the 
insertion, as it will be explained later. The amplification program in the thermocycler 
consisted in an initial denaturation step at 95°C for 30 seconds, followed by 12 cycles of 
denaturation at 95°C for 30 seconds, annealing at 55°C for 1 minute and extension at 
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68°C for 6 minutes. After the thermal cycling reaction the products were set on ice for 2 
minutes. 
After the extension, the amplified product was treated with an endonuclease 
provided in the kit, Dpn I, which digests the parental methylated and hemimethylated DNA 
template, thus allowing the selection of the newly synthetized mutated DNA (step 2- 
Figure 19). The reaction consisted on adding 10U of the endonuclease to each 
amplification reactions, followed by incubation on the thermocycler for 1 hour at 37°C. 
Lastly, XL1-Blue supercompetent cells were transformed with the vectors 
containing the desired mutations by mixing 4µl of the DNA product treated with Dpn I with 
50µl of supercompetent cells. pUC18 control plasmid was also transformed in parallel to 
evaluate the efficiency of the transformation. The transformation procedure was identical 
of that described before using Stellar™ Competent Cells. Bacteria transformed with the 
mutated plasmids were plated in LB agar containing 25µg/ml of kanamycin, and 
pWhitescript and pUC18 controls, plated in LB agar containing 50µg/ml of ampicillin. For 
the pWhitescript and pUC18 transformations, 40µl of blue-white select screening reagent 
(40mg/ml of X-Gal and 40mg/ml of IPTG- Sigma-Aldrich) were added to the selective LB 
medium. After transformation, pWhitescript and pUC18 colonies expressing full-length β-
galactosidase appeared blue. 
Single colonies were picked from each LB agar plate transformed with the different 
plasmids, and cultured in liquid LB (without agar), at 37ºC for 15.5 hours in the 
Thermolyne ROSI 1000™ shaking incubator. Cells were pelleted by centrifugation in the 
centrifuge 5810 R (Eppendorf, Hamburg, Germany) for 30 minutes at 3220rcf. Then, the 
plasmid DNA was extracted using the NucleoSpin® Plasmid kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s instructions, and the identity of each plasmid 
was confirmed by Sanger sequencing.  
Before proceeding to the transfection of prostate cell lines, an empty vector to 
serve as control was created using the original HOXB13 expression vector. The ORF was 
excised with two restriction enzymes, FastDigest Sal I and FastDigest Xho I (Thermo 
Scientific) and then the plasmid was re-ligated with 5U/µl of T4 DNA Ligase (Thermo 
Scientific).  
For the digestion reaction, 2µg of plasmid DNA (HOXB13 wild-type), 1xFastDigest 
Green Buffer, 2µl of FastDigest Sal I and 2µl of FastDigest Xho I (all from Thermo 
Scientific) were used, in a final volume of 20µl in ddH2O.  The reaction was incubated in a 
thermocycler at 37ºC for 1 hour followed by enzyme inactivation at 65ºC for 10 minutes. 
The mix was loaded in a 1.5% (w/v) agarose gel stained with ethidium bromide, to 
separate the bands, with the heaviest band being the empty, linearized plasmid, and the 
lighter band the HOXB13 insert. After electrophoresis, the heaviest DNA band was cut 
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under UV light and purified with the illustra™ GFX™ PCR DNA and Gel Band Purification 
Kit, from GE Healthcare. The basic procedure consists on dissolving the agarose with a 
chaotropic agent, then binding the DNA to a glass fiber matrix, followed by the wash of 
proteins and salt contaminants. Lastly, the DNA was eluted in a low ionic strength buffer. 
After the digestion, the linear vector was re-ligated. For this reaction 50ng of the linear 
DNA were combined with 1xT4 Buffer (Thermo Scientific), 0.1U of T4 DNA ligase (Thermo 
Scientific) and nuclease-free water in a final volume of 50µl. This vector was also 
expanded in Stellar™ Competent Cells and purified as previously described, and its 
identity was confirmed by Sanger sequencing. 
The transformation procedure is schematically summarized in Figure 20. 
 
 
Figure 20 - Transformation of competent cells with the desired plasmids [adapted from 
http://www.acgtinc.com/dna_rna_extraction.htm]. 
To simplify nomenclature, the empty vector will be referred as p-Entry and the 
mutated vectors as HOXB13-G84E and HOXB13-A128D. 
3.3 Transfection and selection of the transfected cells 
After expansion and isolation of the four vectors (p-Entry, HOXB13-WT, HOXB13-
G84E and HOXB13-A128D), these were transfected into the chosen cell lines, using the 
TurboFectin 8.0™ transfection reagent (Origene). TurboFectin is a lipid/histone based 
transfection reagent recommended by Origene for the transfection of TrueORF clones, for 
gene overexpression. Having in mind the criteria mentioned before, the cell line availability 
at our lab, as well as the results regarding HOXB13 sequencing and expression levels 
(shown later), the chosen prostate-derived cell lines were 22Rv1 and PNT2.  
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One day before transfection, 22Rv1 and PNT2 cells were plated in 60mm Petri 
dishes at a density of 5x105 cells and 1,5x105, respectively, in complete RPMI-1640 
medium (GIBCO®), in order to reach a confluence of approximately 60% at the day of 
transfection. In the day of transfection, 250µl of Opti-MEM medium (GIBCO®) were mixed 
with TurboFectin 8.0™ (one for each vector and cell line) and incubated at room 
temperature for 5 minutes. The DNA from each vector was added to the complex formed 
before, and incubated at room temperature for 30 minutes. Three different ratios of 
TurboFectin-DNA were used for each vector, in order to achieve the best transfection 
efficiency:  
 3:1 – 7.5µl  of TurboFectin for 2.5µg of DNA; 
 3:2 – 7.5µl  of TurboFectin for 5µg of DNA; 
 6:1 – 15µl of TurboFectin for 2.5µg of DNA. 
The TurboFectin-DNA containing mixtures were then added drop-wise to the cells 
and incubated for 48 hours at 37ºC with 5% CO2. The transfection scheme is illustrated in 
Figure 21. 
 
Figure 21 - Schematic representation of the transfection strategy. PNT2 and 22Rv1 cell lines were 
simultaneously transfected with the four vectors, each with three different transfection conditions (TurboFectin-
DNA ratios). 
 52 
 
After 48 hours, the cells were cultured in selective medium - complete RPMI 
medium supplemented with G418 (GIBCO®). The concentrations of G418 that induced 
more than 50% of cell death in 24-48 hours - 900µg/ml for 22Rv1 and 450µg/ml and for 
PNT2 – were selected to establish stable cell populations, which was achieved after 4 to 5 
weeks. 
4. Phenotypic assays 
In order to have an insight into the biological role of HOXB13 and the phenotypic 
impact of the G84E and A128D mutations, two different phenotypic assays were 
performed. These assays were only performed in the PNT2-derived cell populations, as it 
will be explained later.  
4.1 Cell proliferation assay: MTT colorimetric assay 
The MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) colorimetric 
assay was first described by Mosmann in 1983, and allows reliable and accurate 
quantification of the number of viable growing cells in proliferation and cytotoxicity studies, 
using a spectrophotometer. The basic principle consists on the cleavage of the yellow 
MTT to formazan (blue/purple) by the mitochondrial reductases, with the number of living 
cells being directly proportional to the amount of formazan formed  (Denizot and Lang, 
1986; Gerlier and Thomasset, 1986; Mosmann, 1983; Sylvester, 2011).  
PNT2-derived cell populations were plated in 96-well plates at a density of 1x104 
cells per well. After plating, cells were incubated at 37ºC with 5% CO2 and evaluated in 
five time points (0, 24, 48, 72 and 96 hours) after adherence. At each time point, culture 
medium was removed and 100µl of MTT solution (Sigma-Aldrich) at 0.5mg/ml in complete 
growth medium were added. After an incubation period of 2 hours, which is the time 
required for the formation of formazan crystals, the MTT solution was removed from the 
wells and 50µl of dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany), were added to 
dissolve the crystals (Figure 22). The 96-well plate was then placed in the FLUOstar 
Omega microplate reader (BMG Labtech, Ortenberg, Germany), and the optical density 
was measured at a wavelength of 540nm with background correction at 630nm. The 
results were analyzed with the Omega Data analysis software (BMG Labtech). 
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Figure 22 - Schematic representation of the MTT colorimetric assay to quantify cell viability [adapted 
from (Ali-Boucetta et al., 2011)]. 
Two independent experiments were done, each including nine wells per condition. 
Data was expressed as a ratio of the results obtained with each transfected cell line and 
the control vector. The statistical analysis was performed using the Student’s t test and 
the data was considered statistically significant when the p values were below 0.05. 
4.2 Cell apoptosis assay 
The term “apoptosis” was first proposed in 1972 by Kerr, Wyllie and Currie (Kerr et 
al., 1972), as being a different form of cell death with some particular morphologic 
characteristics, like condensation of the nucleus and the cytoplasm, accompanied with the 
breaking up of the cell into fragments. Nowadays, apoptosis is considered a programmed 
cell death, occurring as a homeostatic process during development processes and aging, 
and also as a protective mechanism against noxious agents and diseases (Elmore, 2007). 
Aberrations in this genetically determined process have been implicated in autoimmune 
and neurodegenerative diseases, heart conditions and cancer (Saddick, 2013).  
To evaluate and quantify apoptosis levels the APOPercentage™ Apoptosis Assay 
kit (Biocolor, County Antrim, UK) was used. During apoptosis, phosphatidylserine that is 
usually in the inner part of the mammalian cell membrane is translocated to the outer part. 
This movement allows the binding of the dye used that is incorporated into the committed 
cell (Figure 23). As the cell shrinks, the dye becomes more concentrated, since this 
accumulation is unidirectional but it can be chemically released. The amount of released 
intracellular dye can then be measured using a microplate colorimeter. 
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Figure 23 - Schematic representation of the asymmetric phospholipd composition of a viable and an 
apoptotic mammalian cell membrane. In a viable cell, the membrane is asymmetric and is maintained by 
enzymes called flippases. In opposition, in apoptotic cells, the activity of these enzymes is compromised and 
is inactivated by other enzymes, termed floppases [adapted from the Biocolor’s protocol, available at 
www.biocolor.co.uk]. 
In this assay, PNT2-derived cell populations were seeded in 96-well plates at a 
density of 1x104 cells per well, and incubated at normal growth conditions with RPMI 
medium for 96 hours. Besides the three replicates per condition, two additional wells were 
used as positive apoptotic controls, in which the medium was substituted by an apoptotic 
inducer (hydrogen peroxide at 10mM) 2 hours before the assay. For apoptosis evaluation, 
100µlof APOPercentage dye dissolved in medium (1:20) were added to each well. After 2 
hours of incubation, the dye was removed and cells were washed twice with 200µl of PBS 
to remove the excess of unbound dye. The dye was released from the apoptotic cells 
using 100µl of APOPercentage dye release reagent and the absorbance was measured in 
the FLUOstar Omega microplate reader (BMG Labtech) at 550nm with background 
correction at 630nm. The results were analyzed with the Omega Data analysis software 
(BMG Labtech). 
Three independent experiments were performed, and results are expressed as a 
normalized ratio of each transfected cell line and the empty vector. The Student’s t test 
was performed and a p value less than 0.05 was considered statistically significant.  
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5. Exon-array data to compare HOXB13 mRNA expression in 
PCa samples from different molecular subtypes  
For the analysis of HOXB13 mRNA expression levels in tumor samples from 
different ETS subgroups, we used the data obtained from exon-level expression 
microarrays that had previously been performed by our group (Paulo et al., 2012b). As 
described, we used a series of 48 tumor samples selected from the consecutive series of 
200 clinically localized PCa, already typed for ETS rearrangements (Paulo et al., 2012a). 
They represented different molecular subtypes, namely 21 samples with ERG 
rearrangement, 11 samples with ETV1 rearrangement, two samples with other ETS 
rearrangements (one with ETV4 and one with ETV5 rearrangements), and 14 samples 
without known ETS. Nine normal prostate tissues (NPTs) obtained from 
cystoprostatectomies (CPs) were also screened for control purposes.  
Briefly, RNA was extracted and 1µg was processed into cDNA and hybridized to 
GeneChip Human Exon 1.0 ST arrays. To obtain gene-level Robust Multi-array Average 
(RMA)-normalized expression values, the Affymetrix Expression Console v1.1 software 
was used (Paulo et al., 2012b).  
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1. HOXB13 Mutation Analysis 
1.1 Primary prostate carcinomas 
Sequences were analyzed using the Sequencing Analysis Software v5.4 (Applied 
Biosystems) and the Mutation Surveyor V4.0.7 (Softgenetics). Of the 178 prostate 
carcinomas sequenced, one heterozygous alteration was found in one case (P308T), at 
the position 383 of exon 1 (Figure 24). The mutation consists of a nonsynonymous 
substitution of an adenosine for a cytosine (transition, c.383C>A) in the second position of 
codon 128 (GCC→GAC), resulting in a nonconservative substitution of aspartic acid for 
alanine. According to the Human Genome Variant Society (HGVS) nomenclature, this 
alteration should be referred to as p.Ala128Asp. This mutation has not been described in 
any published article or in any of the databases consulted, namely, Exome Variant Server, 
dbSNP (the database of known DNA sequence variants from NCBI), COSMIC (Catalogue 
of somatic mutations in cancer), or Ensembl, the last two from the Wellcome Trust Sanger 
Institute.  
In order to determine the somatic or germline nature of the mutation found in the 
tumor tissue, a DNA sample was extracted from peripheral leukocytes and sequenced, 
and it was demonstrated that the mutation was present in the germline. 
 
 
Figure 24 - DNA sequence chromatogram obtained from PCa tissue from the patient with the HOXB13 
c.383C>A, p.Ala128Asp variant. 
The possible effect of this missense mutation on the structure and function of the 
HOXB13 protein was evaluated using the Polymorphism Phenotyping v2 (PolyPhen-2) 
software that uses sequence and structure-based information for prediction (Adzhubei et 
al., 2013). Two pairs of datasets from the software were used to evaluate potentially 
deleterious effects (HumanVar and HumanDiv). The first contains 13,032 human disease-
causing mutations from the UniProt database, as well as 8,946 human nonsynonymous 
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SNPs without annotated involvement in disease. HumDiv was compilled from 3,155 
damaging alleles annotated in the UniProt as causing Mendelian diseases and affecting 
protein function or stability, with 6,321 differences between human proteins and their 
related mammalian homologs (Adzhubei et al., 2010). According to the two datasets, the 
A128D alteration is predicted to be probably damaging to protein function, with a 
probability of 0.997 by the HumVar and 1 by the HumDiv (Figure 25). 
 
 
 
 
 
 
Figure 25 - Scores of the predicted effect of HOXB13 c.383C>A, p.Ala128Asp variant in protein 
function obtained with the two PolyPhen datasets (HumVar, above and HumDiv, below).  The score 
increases from green to red, with a higher score meaning an increased damage to protein function [adapted 
from PolyPhen software available at http://genetics.bwh.harvard.edu/pph2/]. 
Besides the A128D variant, we have also found the two synonymous variants in 
exon 1, c.366C>T and c.513T>C, which do not change the encoded aminoacid. These 
variants have already been described as being SNPs, with the dbSNP IDs being rs8556 
and rs9900627, respectively (Ewing et al., 2012; Lin et al., 2013). Both SNPs were found 
in 36 subjects in our study, with a frequency of approximately 20%. 
1.2 Prostate cell lines 
The LNCaP, PNT2, 22Rv1 and NCI-H660 prostate cell lines were sequenced to 
select our study cell model.  Only LNCaP presented an alteration in HOXB13, c.431T>C 
(Figure 26), resulting in a nonsynonymous heterozygous substitution of a proline for a 
leucine at codon 144, p.Leu144Pro (L144P), which is located in the second MEIS 
interacting domain (Ewing et al., 2012; Williams et al., 2005). 
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Figure 26 - DNA sequence chromatogram obtained from the PCa cell line LNCaP. 
 
2. Induction of de novo overexpression of HOXB13 in prostate 
cell lines 
2.1 Selection of the study cell model 
HOXB13 mRNA expression levels in the cell lines was evaluated using 
quantitative real-time PCR (Figure 27). NCI-H660, DU145 and PNT2 do not express 
HOXB13, in opposition to the other prostate cancer cell lines, with MDA-PCa-2b being the 
cell line with higher expression levels, followed by LNCaP, PC-3, 22Rv1, and VCaP.  
 
Figure 27 - HOXB13 expression levels in eight prostate cell lines using quantitative real-time PCR. 
HOXB13 expression at the protein level was also evaluated, using Western Blot 
(Figure 28). As demonstrated by qRT-PCR, MDA-PCa-2b is the cell line with higher 
expression levels of HOXB13, and LNCaP, VCaP, 22Rv1 and PC-3 also show expression 
of this protein. NCI-H660, DU145 and PNT2 do not express HOXB13. 
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Figure 28 - Expression of HOXB13 in eight prostate cell lines, evaluated by Western blot.  
After evaluation of HOXB13 mutation status and HOXB13 expression levels in the 
available prostatic cell lines, the choice to establish HOXB13 models of prostatic 
carcinogenesis could be made. As it was mentioned before, two prostatic cell lines with no 
HOXB13 mutations were chosen. 
To explore if the de novo overexpression of HOXB13 and its mutated forms are 
somehow involved in PCa initiation, PNT2, a non-malignant prostate-derived cell line was 
chosen. PNT2 was chosen since it was the only non-malignant cell line available at our 
lab, and it has minor expression and no mutations of the HOXB13 gene.  
For the malignant context, 22Rv1 was the PCa-derived cell line that best fited in 
the defined criteria, altough its HOXB13 expression is not as low as we would prefer. The 
other cell lines did not fulfilled the criteria for different reasons:  LNCaP was excluded 
because it has a nonsynonymous mutation in the HOXB13 gene; MDA-PCa-2b was 
shown to have high HOXB13 expression levels and it has the MIPOL1:ETV1 
rearrangement; VCaP and NCI-H660 also harbor an ETS rearrangement 
(TMPRSS2:ERG) and the latter is androgen-independent; and PC-3 and DU145 were 
also excluded because they are androgen-independent. We excluded all the cell lines with 
ETS rearrangements because the tumor sample with the A128D mutation does not harbor 
any rearrangement, (Paulo et al., 2012a) and these could eventually interfere with 
HOXB13 expression in our in vitro models. 
2.2 Confirmation of site-directed mutagenesis in the HOXB13 expressing 
vectors 
As mentioned before, Sanger sequencing was performed to confirm the success of 
the mutagenesis. The mutagenesis was indeed successful, since we could induce the 
substitution of an adenosine for a guanine to construct the vector with the G84E mutation 
(Figure 29), and the substitution of an adenosine for a cytosine to construct the vector 
harboring the A128D mutation (Figure 30). 
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Figure 29 - DNA sequence chromatogram obtained from the vector with the G84E mutation.  
 
Figure 30 - DNA sequence chromatogram obtained from the vector with the A128D mutation.  
3. Analysis of HOXB13 overexpression in transfected cell lines 
 After the transfection of 22Rv1 and PNT2 cell lines with the four different vectors 
(p-Entry, HOXB13-WT, HOXB13-G84E and HOXB13-A128D), the expression of HOXB13 
in the altered cells was evaluated by quantitative real-time PCR (Figures 31 and 32).  
 
 
Figure 31 - HOXB13 expression levels in 22Rv1 transfected cells, normalized for the correspondent 
control vector, using quantitative real-time PCR. 
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As it can be observed in Figure 31, there are virtually no differences in the levels of 
HOXB13 expression between the cells transfected with different HOXB13 expression 
vectors and the control vectors (p-Entry). It remains to be clarified whether the observed 
HOXB13 expression is due to “silencing” of the exogenous or the endogenous HOXB13, 
as these cell populations are resistant to the selective antibiotic. For the purpose of this 
Thesis, these 22Rv1 established cell populations were not useful and no further studies 
were done with them.  
 
Figure 32 - HOXB13 expression levels in PNT2 transfected cell populations, normalized for the 
correspondent control vector, using quantitative real-time PCR. 
Regarding PNT2 transfected cell populations (Figure 32), the expression levels 
vary not only depending on the vector that was inserted, but also between different 
transfection conditions (TurboFectin-DNA ratio). In fact, there is not a common 
transfection condition that is more efficient than the others. Due to this fact, for each 
HOXB13 expressing vector, we decided to choose two populations to pursue our studies 
taking the expression levels into account. Thus, the two transfection conditions of each 
vector with higher HOXB13 expression were selected. Regarding the control vector (p-
Entry), as there were no significant differences between the three established populations, 
one was randomly chosen. The selected cell populations and their HOXB13 expression 
levels normalized for the control vector are represented in Figure 33. 
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Figure 33 - HOXB13 expression levels in the selected PNT2 transfected cells, normalized for the 
control vector, using quantitative real-time PCR. 
4. Biological role of HOXB13 – phenotypic assays 
In order to investigate a potential oncogenic role of HOXB13 in prostate 
carcinogenesis, two phenotypic assays, namely MTT proliferation assay and apoptosis 
assay, were performed as previously described. 
4.1 Cell proliferation assay 
The role of HOXB13 and its mutated forms, G84E and A128D, in cell proliferation 
was evaluated in vitro using the MTT colorimetric assay. Proliferation results were only 
considered for three different time-points, because the growth rates obtained for the 24 
and 48 hours’ time-points were not consistent between experiments. 
The overexpression of the wild-type form of HOXB13 has shown to have a growth 
stimulatory effect on PNT2 cell line at 72 hours. However, this effect was only statistically 
significant for one of the overexpressing populations (P1; p=0.03), being borderline for the 
other cell population (P2; p=0.054). This tendency is maintained at 96 hours, although the 
values do not reach statistical significance. Because these data were obtained from only 
two independent experiments, additional replicates will strengthen the significance of the 
results. None of the mutations seem to alter PNT2 growth rate when compared to the 
control vector (Figure 34). 
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Figure 34 - Quantification of cell viability in PNT2- derived cells (p-Entry, HOXB13-WT, HOXB13-G84E 
and HOXB13-A128D) evaluated at two different time-points (72 and 96 hours). Bars represent standard 
deviation. 
4.2 Cell apoptosis assay 
We evaluated if the overexpression of HOXB13 and of its two mutated forms could 
influence apoptosis in PNT2-derived cell populations, and quantitative analysis was 
performed through the measurement of the concentration of the dye used, in a microplate 
reader.  
We observed that cells with overexpression of HOXB13-A128D variant have 
decreased apoptotic rates when compared to the control (Figure 35). This result was 
statistically significant (p=0.02) for the P2 population and borderline for the P1 population. 
The wild-type form of HOXB13 and the mutated form G84E do not seem to influence cell 
death through apoptosis in vitro. As for the MTT assay, and although these data were 
obtained from three independent experiments, additional replicates may strengthen these 
observations. 
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Figure 35 - Quantification of apoptotic rates in PNT2 derived cells (HOXB13-WT, HOXB13-G84E, 
HOXB13-A128D and in the control vector – p-Entry), evaluated after 96h in culture. Bars represent 
standard deviation. 
5. HOXB13 mRNA Expression Pattern by Molecular Subtype  
HOXB13 mRNA expression levels were evaluated in NPTs and in prostate tumors 
from different molecular subtypes, using the exon-array data available from our group. 
When we compared HOXB13 expression between all PCa and NPTs, no statistically 
significant differences were found (Figure 36). Regarding HOXB13 mRNA expression 
levels in prostate tumors, we have observed differences between different molecular 
subtypes, although these were not statistically significant (Kruskal-Wallis test, p value = 
0.053). For the several two-group comparisons, Mann-Whitney tests were performed, and 
a significantly higher expression of HOXB13 was observed in tumors with ETS 
rearrangements involving the PEA3 family members (ETV1, ETV4 and ETV5) when 
compared to ERG-positive tumors (p value = 0.004), as illustrated in Figure 37.  
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Figure 36 - Boxplot representing HOXB13 mRNA expression in NPTs and in prostate carcinomas. RMA 
- Robust Multi-array Average. 
 
Figure 37 - Boxplot representing HOXB13 expression in the different PCa ETS subgroups and in 
normal mucosa obtained from CPs. RMA - Robust Multi-array Average. 
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The HOX genes are highly conserved genes that belong to the homeobox 
superfamily of transcription factors, and their coordinated expression is responsible for the 
correct pattern formation of the body, during embryonic development (Daftary and Taylor, 
2006; Ewing et al., 2012; Jung et al., 2004b). Deregulation of their expression have been 
associated with many types of neoplasias, such as PCa; however, the mechanisms by 
which they promote carcinogenesis are not entirely understood and could be different 
depending on the type of malignancy (Chen and Sukumar, 2003; Gray et al., 2011; Habel 
et al., 2013; Jung et al., 2005; Kelly et al., 2011; Zhao et al., 2005).  
HOXB13, such as other HOX13 paralogs, is very important for normal prostate 
development (Economides and Capecchi, 2003; Huang et al., 2007), but it is the only that 
continues to be expressed through adulthood and its expression levels are also 
maintained in PCa (Ewing et al., 2012; Jung et al., 2004a; Jung et al., 2004b; Kim et al., 
2010b). The role of HOXB13 in prostate carcinogenesis remains elusive so far, with some 
studies implicating HOXB13 as a TSG and others as an oncogene, and its mode of action 
seems to depend on the cellular environment and on the cell type (Jung et al., 2004a; 
Jung et al., 2004b; Kim et al., 2010b). 
More recently, some germline mutations were described in the HOXB13 gene, 
namely G84E in populations of European descent (Ewing et al., 2012) and G135E in 
Chinese men (Lin et al., 2013), which seem to confer a higher risk for PCa development. 
However, the exact mechanisms by which they promote carcinogenesis are not 
understood. Furthermore, it is unknown if HOXB13 somatic mutations play a role in 
prostate cancer in addition to inherited predisposition. We therefore started by searching 
for HOXB13 variants in prostate carcinomas, with the idea to test any mutation found for 
its somatic or germline nature. 
1. HOXB13 mutation analysis in primary prostate carcinomas 
The recurrent mutations G84E and G135E respectively in Western and Chinese 
populations (Ewing et al., 2012; Lin et al., 2013) were not detected in this series. While it 
was not expected that the Chinese mutation would be found, we cannot completely 
exclude that the G84E mutation exists in our population because of the limited number of 
cases analyzed. However, this variant is known to be more frequent in the Nordic 
countries than in South Europe. 
Interestingly, we here describe for the first time the presence of the 
nonsynonymous mutation p.Ala128Asp in the HOXB13 gene, which, like the other 
mutations so far detected, is a heterozygous germline mutation. It is important to mention 
that, like in G84E carriers, HOXB13 expression is maintained. This variant was predicted 
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to be probably damaging to protein function by two different in silico analyses (Adzhubei 
et al., 2013). The patient carrying this germline mutation had prostate cancer, bladder 
cancer and gastric cancer diagnosed at 65, 58 and 74 years of age. Since his family 
history is otherwise unremarkable besides a sister with gastric cancer, it would be 
important to test additional relatives to find out who else is at risk and if this is a de novo 
germline mutation.  
It is conceivable that we would find additional cases with HOXB13 germline 
mutations if we increased our sample size and if we had selected patients with a positive 
family history or early-onset of the disease, instead of sequencing DNA from a 
consecutive series of prostate carcinomas. However, this strategy was appropriate for our 
initial purpose of finding somatic HOXB13 mutations, while at the same time having the 
possibility to test if any detected variant was somatic or germline, which was exactly what 
happened in this case. To assess the importance of this novel variant in PCa 
susceptibility, it will be essential to evaluate not only more cases (subjects with PCa) but 
also controls, in order to estimate the relative risk of PCa development. Nevertheless, the 
discovery of this new genetic variant further implicates HOXB13 in prostate 
carcinogenesis, and different populations may have their own founder mutations 
predisposing to prostate cancer. 
Regarding the two SNPs found, rs8556 and rs9900627, they were found with 
similar frequencies as those previously reported (Ewing et al., 2012). Although many 
SNPs associated with PCa risk have already been described (Karlsson et al., 2012; Xu et 
al., 2013), the odd ratios (ORs) are so low that it prevents their use in clinical practice 
(Akbari et al., 2012).  
2. Biological role of HOXB13 
Given the importance of HOXB13 in prostate biology and since there is still a 
debate surrounding its importance in prostate carcinogenesis, we tried to clarify if it 
behaves like a TSG or like an oncogene. We also intended to gain insight on the 
phenotypic consequences of the G84E mutation and of the new A128D variant discovered 
in this work, so we investigated for the first time the potential oncogenic role of these 
mutations in prostate carcinogenesis.  
2.1 Selection of the study cell model 
To choose our study models, HOXB13 was first sequenced in three prostate cell 
lines, NCI-H660, PNT2 and LNCaP, to verify if they harbored any HOXB13 mutations. The 
first two have not been sequenced yet by any other group (or at least it has not been 
published), but we found no mutations. Regarding LNCaP, we have confirmed the 
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presence of a nonsynonymous mutation, p.Leu144Pro, already described by Ewing and 
collaborators (Ewing et al., 2012). Besides performing Sanger sequencing, we have also 
evaluated HOXB13 expression both at the mRNA and protein level. The pattern of 
expression of HOXB13 in our cell lines was similar to those described in the literature 
(Jung et al., 2004b; Kim et al., 2010b), except for the PC-3 cell line. It has been described 
that only AR-expressing prostate cells express HOXB13 (Jung et al., 2004b; Kim et al., 
2010b) and PC-3, being an AR-negative PCa cell line, should not express HOXB13. 
Regarding NCI-H660 and VCaP, the obtained results are consistent with their AR status: 
VCaP expresses HOXB13, while NCI-H660 (AR-negative) only presents minor 
expression. 
22Rv1 and PNT2 were the chosen cell lines where we induced de novo 
overexpression of the HOXB13-WT form and HOXB13 mutated forms. However, we could 
not increase HOXB13 expression in the 22Rv1 PCa-derived cell line. It was confirmed by 
qRT-PCR and by immunoblotting that the 22Rv1 wild-type already expresses HOXB13, 
and we do not know for sure what the transfected cells are expressing. As mentioned 
before, these cell populations are resistant to the selective antibiotic, so the transfection 
was not the problem. It is possible that the transfected cells might be “silencing” the 
exogenous or the endogenous HOXB13, by an unknown mechanism. Using a specific 
antibody for the exogenous HOXB13 (4C5-AntiDDK monoclonal antibody) would allow 
clarifying this phenomenon. Thus, only PNT2 was used as a cell model to study cell 
proliferation and apoptosis. 
2.2 Phenotypic assays 
Functional evaluation revealed that overexpression of HOXB13-WT in PNT2-
derived cells influences their proliferative phenotype, with an increase in cell proliferation. 
These results were only statistically significant for one time-point (72 hours), but this 
tendency was also present for the other evaluated time-point. This might be due to the 
fact that only two independent experiments were performed, and increasing the number of 
experiments would increase the consistency of the results. The results only reached 
statistical significance for the P1 population, and one possible explanation might be the 
fact that this population expresses more HOXB13 than P2. This increase in cell 
proliferation was consistent with another study, although in a different cell line (Kim et al., 
2010b), where the overexpression of HOXB13 in the LNCaP PCa-derived cell line 
markedly promoted cell proliferation in the absence of androgens, by inhibiting the 
expression of the p21 TSG that activates the RB-E2F signaling, as explained before. The 
results obtained by Kim and collaborators indicate that HOXB13 overexpression confers a 
growth advantage for PCa cells in an androgen-deprived environment, and could explain 
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why some patients relapse after androgen ablation (Kim et al., 2010a; Kim et al., 2010b). 
In our model, more studies are needed to understand the mechanism by which HOXB13 
overexpression promotes cell proliferation. We also would like to perform the same 
experiment in the presence of androgens, to verify if, in contrast, HOXB13 would have an 
inhibitory effect in cell growth, as described by other groups (Jung et al., 2004a; Jung et 
al., 2004b). Another observation was that apoptosis tended to decrease in PNT2-derived 
cells harboring the A128D mutation. As verified for the cell proliferation assay, the results 
only reach statistical significance for the population with higher HOXB13 expression (P2), 
which might indicate a dose effect. Once more it is possible that by increasing the number 
of independent experiments the significance of the results could be strengthen.   
The results obtained with the two phenotypic assays suggest a carcinogenic 
mechanism consistent with a gain of function, typical of oncogenes. However, more 
studies are needed to confirm this hypothesis. One possible way to confirm these results 
could be by using an opposite approach, such as silencing HOXB13 in a cell line with high 
expression levels, like MDA-PCa-2b, for example, and confirm if the absence of HOXB13 
would have a suppressive effect on cell growth. Although we did not reach any 
conclusions regarding the G84E mutation, in the first description of this mutation (Ewing et 
al., 2012) there was a suspicion that it might also act as an oncogene due to its recurrent 
nature. Since there is a lack of truncating mutations in HOXB13 in patients with PCa 
(Ewing et al., 2012), it is more plausible that both mutations have a gain of function 
mechanism.   
One limitation of our study was the fact that we only evaluated two functional 
capabilities associated to cancer, which were increased cell proliferation and evasion of 
apoptosis.  We also should evaluate if HOXB13 and its mutated forms are somehow 
involved in other hallmarks of cancer, such as tissue invasion and metastasis, since 
sooner or later almost every cancers acquire these abilities, which are the primary causes 
for a fatal outcome  (Behrens, 1993; Hanahan and Weinberg, 2000). Regarding these two 
features, we could perform two phenotypic assays: a colony formation assay that 
evaluates anchorage-independent growth of cancer cells and a cell invasion assay.  
3. HOXB13 mRNA Expression Pattern by Molecular Subtype  
We have also proposed to verify if HOXB13 mRNA expression was altered in 
tumors, when compared to NPTs, but we have not found such global difference. Our 
results are in agreement with other studies (Jung et al., 2004a; Jung et al., 2004b; Kim et 
al., 2010a; Kim et al., 2010b) that state that it is difficult to observe such differences. 
Additionally, those studies reported that different populations of HOXB13-negative and 
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HOXB13-positive cells could be observed in the same tumor, which could be a reasonable 
explanation for the absence of such differences. On the other hand, other studies reported 
a higher expression of HOXB13 in tumors, when compared to the normal prostate 
(Edwards et al., 2005; Grossmann et al., 2001). However, all of these studies used 
matching benign tissue adjacent to tumor site, which has not been obtained by 
microdissection techniques and which raises doubts about the truly benign nature of these 
samples, since PCa is very heterogeneous and usually multifocal.  To avoid these 
problems, here we used NPTs collected from CPs specimens of bladder cancer patients.  
The last goal of this project was to find out if HOXB13 mRNA expression was 
somehow related to the molecular subtype of the tumor, more specifically with different 
ETS subgroups, and we found that HOXB13 was overexpressed in the tumors belonging 
to the PEA3 family. Unfortunately, we have no other studies to compare with our results. 
Since the majority of samples from the PEA3 family were samples with an ETV1 
rearrangement (11 of 13), it will be interesting to study the role of HOXB13 in the ETV1 
context. For that we could use the LNCaP PCa-cell line with ETV1 silencing (shETV1), 
which was already established in our lab, and induce HOXB13 overexpression in the 
presence and absence of androgen stimuli and evaluate the phenotypic impacts. It has 
been previously described that overexpression of HOXB13 in LNCaP has different 
consequences depending on the presence or absence of androgens (Jung et al., 2004b; 
Kim et al., 2010b) and this model will clarified if this opposite effect is in fact only 
dependent on androgens or if, otherwise, is related with ETV1. Additionally, it would be 
interesting to evaluate the phenotypic impact of silencing HOXB13 in the MDA-PCa-2b 
cell line, which also has an ETV1 rearrangement and shows high expression but no point 
mutations in HOXB13. 
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 A new nonsynonymous mutation, p.Ala128DAsp, was identified in the 
HOXB13 gene and was predicted to be damaging to protein structure. This 
reinforces the fact that HOXB13 is involved in prostate cancer 
development. To find more cases harboring this genetic alteration, in the 
future we could screen more cases and select subjects with a family history 
of PCa and early-onset of the disease. 
 By performing functional assays in PNT2-derived cells in the absence of 
androgens, we observed alterations in two hallmarks of cancer, both 
suggesting a potential oncogenic mechanism for HOXB13 in prostate 
carcinogenesis. Specifically, we saw an increase in cell proliferation in cells 
overexpressing the wild-type form of the gene, and a decrease in apoptosis 
in cells overexpressing the novel mutated form A128D. However, more 
replicates are required to strengthen the significance of the results, mainly 
for the cell proliferation assay. 
 To validate the observations of the functional assays performed in the 
PNT2 cell line, we could use an opposite approach, using a PCa-derived 
cell line with HOXB13 expression and perform in vitro silencing. 
 We also intend to verify whether 22Rv1-derived cell populations are 
expressing the exogenous HOXB13, so we will use a specific antibody for 
the exogenous HOXB13. If this expression is confirmed, 22Rv1 PCa-cell 
line could be used, as initially planned, as a cell model to study further the 
role of HOXB13 in prostate carcinogenesis.   
 We also would like to perform more functional assays, like colony formation 
and invasion assays, to see if HOXB13 and its mutated forms are involved 
in other stages of carcinogenesis (tissue invasion and metastasis). All of 
these functional studies should also be replicated in an androgen rich 
environment, to verify if PNT2-derived cells would behave differently.   
 In this study, HOXB13 mRNA levels were compared for the first time 
between different PCa molecular subtypes, and we here report that 
HOXB13 is mainly overexpressed in tumors with ETV1 rearrangements. 
Thus, we aim to study the role of HOXB13 in an ETV1 context, using the 
LNCaP-shETV1 model and the MDA-PCa-2b cell line. 
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